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Autophagy is an essential quality control function of the cell. It selectively 
degrades harmful protein aggregates and/or damaged organelles, enabling 
maintenance of cellular homeostasis. Basal autophagy also mediates proper 
cardiovascular function. A variety of cardiovascular risk factors cause 
defective autophagy, consequently, pharmacotherapy with compounds to re-
establish physiological levels of autophagy and stimulate pro-survival effects 
in the vasculature is an emerging strategy for cardiovascular disease. 
Therefore, it is crucial for the design of new pharmacological therapy the 
identification of novel key genes involved in the regulation of autophagy in 
vascular cells. 
In two recent studies Caporali et al showed how miR-503 might be 
considered a suppressor of postishemic neovascularization in type I diabetes 
and suggested some critical genes targeted by miR-503 whom 
downregulation may be crucial for the detrimental effect on endothelial cells 
and pericyte. Among the putative targets of miR-503 not prioritized in the 
previous studies but of potential interest for endothelial cell functions there 
was TCHP. 
Trichoplein (TCHP) was first identified as a keratin binding protein in 2005 
and was described having a role in cancer progression, cellular apoptosis, 
cell cycle, primary cilium formation, mitochondria fragmentation and 
mitochondria-endoplasmic reticulum tethering. Using biochemical and 
bioinformatics approaches, I have demonstrated that TCHP is a novel target 
of miR-503. The data presented in this thesis will address the hypothesis that 
TCHP regulates endothelial function through the control of autophagy. 
TCHP expression in ECs was reduced when cultivated in high glucose in 
combination with low growth factors condition. Notably, ECs sorted from mice 
with Type-1 diabetes showed low levels of Tchp compared to non-diabetic 
mice. Knockdown of TCHP in ECs in vitro was characterized by marked 




microtubule network, reduced EC migration, reduced barrier function and 
impaired EC sprouting.  Loss of TCHP function in ECs in vitro led to a 
defective autophagy, resulting in accumulation of SQSTM1/p62 and unfolded 
protein aggregates. Therefore, blocking autophagic flux in ECs resulted in 
premature cellular senescence as demonstrated by the appearance of β-
galactosidase staining, the senescence-associated secretory phenotype 
(SASP) and increased expression of p16INK4A.  This phenotype was 
associated with activation of the mTOR pathway and could be rescued using 
mTOR inhibitors. Thus, Torin-1 improved the migratory capacity of TCHP 
knockdown cells and rescued their senescent phenotype. In addition, 
ultrastructure analysis, immunofluorescence and epidermal growth factor 
pulse chase experiments revealed substantial abnormalities in the endosome 
and lysosome compartments in TCHP knock down cells.   
Remarkably, Tchp knockout mice exhibited a decreased cardiac 
vascularization and a significant accumulation of SQSTM1/p62 in cardiac 
vessels and cardiomyocytes, as a demonstration of defective autophagic flux.  
Finally, I observed loss of TCHP and an increase of SQSTM1/p62 and 
aggregates in the vessel wall derived-ECs, from patients with vascular 
dysfunction and premature coronary artery disease. Remarkably ECs from 
patients exhibited impaired migration and increased expression of SASP, 
resembling the phenotype of TCHP knockdown cells. In line with this, 
function in EC from patients was rescued by Torin-1 treatment. 
Taken together, these results reveal for the first time the pivotal role played 
by TCHP in the vascular endothelium and identify a new mechanism by 
which pathological conditions, through the silencing of TCHP, lead to the 
endothelial dysfunction. Importantly, this study highlights a fundamental link 
between EC function and cellular proteostasis, through the control of 







The blood vessels in the human body are lined with a thin layer of endothelial 
cells. In healthy people, endothelial cells help to form new vessels by 
migrating and dividing. In diabetic patients and in patients with dysfunctional 
endothelium, these endothelial cells are faulty and weak, which can lead to 
vessel-related problems like ischemia (lack of blood flow to parts of the 
body), atherosclerosis (hardening of the arteries) and delayed healing of 
wounds. Therefore, it is important to identify proteins that regulate the 
function of endothelial cells because they can be new therapeutic targets.  
I have discovered that a protein called trichoplein (TCHP) helps endothelial 
cells to migrate and to survive, and cells without TCHP are more easily 
damaged by cellular insults. I believe that diabetes and related stresses, 
such as decreased levels of oxygen and growth factor as well as high levels 
of glucose, may cause vessel-related problems by diminishing the levels of 
TCHP in endothelial cells. 
Furthermore, I have observed that low levels of TCHP, reduced a biological 
process called “autophagy”. Often diabetic patients have a defective 
autophagy and malfunctioning of this process has been linked to several 
cardiovascular complications. Autophagy is a cellular process helping the 
cells of our bodies to stay healthy, destroying damaged organelles and 
recycling them into their basic building blocks; or helping them to survive to 
low nutrient conditions, digesting unnecessary portions of the cell to obtain 
energy for essential cellular functions. In fact, I described that endothelial 
cells defective for TCHP expression are engulfed in protein aggregate, 
secrete pro-inflammatory signals and acquire features typical of aged cells. I 
demonstrate a positive correlation between the reactivation of autophagy and 
the improvement of this phenotype. Finally, I found that EC from patients with 
premature coronary artery disease have low levels of TCHP, accumulation of 
protein aggregates, and migratory defects that can be ameliorated by 
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1.1.1 Identification and function 
Trichoplein (TCHP,alias MITOSTATIN) is a cytosolic ubiquitously expressed 
62 kDa protein identified like keratin-binding protein in 2005 using yeast two 
hybrid technique (Nishizawa, Izawa et al. 2005). This protein showed a low 
degree of sequence similarity to trichohyalin, plectin and myosin heavy chain, 
and is a K8/18-binding protein. 
In 2009, the cloning of TCHP was confirmed as a novel protein endowed with 
tumour suppressor activity, located on chromosome 12q24, frequently 
deleted in a variety of malignant neoplasms (Vecchione, Fassan et al. 2009). 
TCHP gene mutation and downregulation have been observed in multiple 
cancers (reduced in 22% of advanced bladder cancer, in 23% of breast 
carcinomas and in 35% of prostate cancer analysed) and its potential as a 
tumour suppressor has been reported recently. In various cancer cell lines, 
the ectopically expressed TCHP inhibited cell growth, migration, invasion, 
adhesion and tumour formation in vivo  (Vecchione, Fassan et al. 2009, 
Fassan, D'Arca et al. 2011). 
TCHP mRNA consist of 3151 base pair (bp) transcript of which 1497 bp are 
the protein coding Open Reading Frame (ORF). The highest RNA expression 
was detected in the heart, skeletal muscle, kidney, liver, and testis. Northern 
Blot analysis performed with TCHP coding sequence (CDS) brought to the 
identification of two additional RNA products a larger 5.5 Kb transcript, 
observed in the heart and skeletal muscle and a smaller 1.24 Kb RNA 
transcript detected only in the heart (Vecchione, Fassan et al. 2009). The 
sequence and regulation of this two additional RNAs as well as their coding 







Figure 1.1 Structure and localization of TCHP 
A, TCHP was identified as a 498aa protein able to bind cytokeratin in 
epithelial cell (Nischizawa M. et al. J Cell Sci. 2005 Mar); B, Localization of 
TCHP in mitochondrial-associated membranes. Modified from Benjamin 
Delprat, Tangui Maurice & Cécile Delettre Cell Death & Disease volume 9, 
Article number: 364 (2018) 
 
 
1.1.2 TCHP and cilium 
TCHP is concentrated at the subdistal/medial region of both mother and 
daughter centrioles and activates centriolar Aurora A kinase in growing cells 
(Inoko, Matsuyama et al. 2012). During ciliogenesis, trichoplein disappears 
from the mother centrioles, and depletion of this protein in cycling epithelial 
cells induces unscheduled primary cilia formation, whereas overexpression 
blocks ciliogenesis, indicating that TCHP negatively controls ciliogenesis at 
the mother centrioles (Inoko, Matsuyama et al. 2012). In proliferating cells, 
TCHP knockdown induced primary cilia formation, resulting in cell cycle arrest 




Recently it has been shown that ubiquitin–proteasome system removes 
TCHP from the mother centrioles and thereby causes Aurora A inactivation, 
leading to ciliogenesis (Kasahara, Kawakami et al. 2014). 
 
1.1.3 TCHP and cytoskeleton 
TCHP binds the centrosomal proteins Odf2 and Ninein, regulating Ninein 
recruitment to the centrosome, resulting therefore indispensable to  
microtubules-anchoring activity of Ninein at the centrosome (Ibi, Zou et al. 
2011). Noteworthy, Ninein appears to have a cytoplasmic distribution in 
pericyte and endothelial cells (ECs) with a markedly increased expression in 
tip versus stalk cells (Matsumoto, Schiller et al. 2008). Migrating ECs have a 
highly polarized structure, with the appearance of membrane ruffles at the 
leading edge and asymmetrical localization of signalling molecules and the 
cytoskeleton (Lamalice, Le Boeuf et al. 2007). There is a growing body of 
evidence that coordinated action of microtubules and actin filaments is 
necessary for the cell polarization and migration (Li and Gundersen 2008). 
Thus, the above evidence could support an important role for TCHP in 
regulating EC migration and angiogenesis. 
 
1.1.4 TCHP and mitochondria 
Recent studies indicate that TCHP plays an important role in the physiology 
of mitochondria. It was reported that TCHP reside on outer mitochondrial 
membrane (OMM) where take contact with Mitofusin2 (Mfn2) promoting a 
fission-like phenotype and a redistribution of mitochondria near the nuclear 
membranes(Vecchione, Fassan et al. 2009, Cerqua, Anesti et al. 2010). 
Moreover, TCHP regulates ER–mitochondria tethering via Mfn2 acting as a 
negative modulator of ER–mitochondria juxtaposition and conferring H2O2 
induced cell death resistance (Cerqua, Anesti et al. 2010). Furthermore, in a 
breast cancer cell model was recently described that increased level of TCHP 
enables decorin evoked mitophagy through a peroxisome proliferator-




Interestingly, the authors reported that depletion of TCHP causes an 
increased production and release of VEGFA (Neill, Torres et al. 2014).  
Recently, it has been reported that keratins, likely through TCHP-mtf2 
interactions, regulate both structural and dynamic functions of β-cell 
mitochondria, which could have implications for downstream insulin secretion 
(Silvander, Kvarnstrom et al. 2017). Therefore, the mitochondrial network in 
primary cultured K8 knockout β cells is more fragmented compared with wild-
type mitochondria, correlating with decreased levels of mtf2 and TCHP. K8 
knockout β-cell mitochondria have decreased levels of total and mitochondrial 
cytochrome c, which correlates with a reduction in electron transport 
complexes I and IV. This provokes loss of mitochondrial membrane potential 
and reduction of ATP and insulin amount (Silvander, Kvarnstrom et al. 2017). 
 
 
1.2 Endothelial cell function 
 
1.2.1 Angiogenesis: definition  
Angiogenesis is creation of new vessels from pre-existing ones (Risau 1997). 
A number of recent studies have provided great insight into the molecular 
mechanisms underlying this process, and led to an established mechanistic 
framework of vessel branching (Carmeliet and Jain 2011) (Potente, Gerhardt 
et al. 2011). Hypoxia is one of the key drivers of the process, and together 
with an array of pro-angiogenic signals, ECs respond to hypoxia by becoming 
motile and protrude filopodia. These aptly named tip cells, advance into the 
microenvironment, leading trailing stalk cells that establish a lumen and 
proliferate to support sprout elongation. Vessel loops are created by the 
anastomosis of neighbouring tip cells, and the initiation local blood flow 
alongside the recruitment of pericytes, and establishment of the basement 
membrane, stabilise these new connections. Remodelling and pruning of the 
newly established vascular network allow fine tuning to suit the needs of the 
local microenvironment and once the pro-angiogenic signals cease, the ECs 




A crucial step in the liberation of ECs during branching is the detachment of 
the pericyte (Carmeliet 2005). The quiescent vessel detects an angiogenic 
signal, such as VEGF, which stimulates ECs to release ANG-2, and in turn 
prompts pericytes to unshackle themselves from the basement membrane by 
proteolytic degradation (Augustin, Koh et al. 2009). This process is primarily 
mediated by matrix metalloproteinases (MMPs) (Arroyo and Iruela-Arispe 
2010). ECs then loosen their junctions, and the vessels dilate. VEGF signals 
the endothelial cell layer to increase its vascular permeability, leading to the 
extravasation of plasma proteins, and consequently the initial extracellular 
matrix (ECM) scaffolds are constructed. Further angiogenic factors are 
released from the ECM via proteases to create a pro-angiogenic milieu, and 
in order to prevent ECs moving en masse, one endothelial cell, known as the 
tip cell, is selected to lead the advance (Adams and Alitalo 2007). 
Neighbouring cells assume an ancillary role as stalk cells, which divide to 
elongate the new vessel and establish a lumen. The precise specification of 
tip and stalk cells is governed by the NOTCH signalling pathway (Phng and 
Gerhardt 2009, Eilken and Adams 2010). Stalk cells appear to have high 
levels of NOTCH signalling, unlike tip cells that possess relatively low levels. 
Conversely, tip cells express high levels of the NOTCH ligand DLL4. An 
integrated, intracellular, negative feedback network has been proposed to 
develop between VEGF and NOTCH (Bentley, Mariggi et al. 2009, Potente, 
Gerhardt et al. 2011). VEGF stimulates tip cell induction and filapodia 
formation via VEGF receptor-2 (VEGFR2), and enhances DLL4 expression in 
the same cells. However, DLL4-mediated activation of NOTCH in 
neighbouring ECs inhibits tip cell behaviour by down-regulating VEGFR2 and 
VEGF receptor-3 (VEGFR3), while up regulating VEGF receptor-1 (VEGFR1) 









1.2.2 Mechanisms of angiogenesis 
 
1.2.2.1 Hypoxia: 
The principal signalling pathway induced by hypoxia involves the activation of 
a transcription factor, hypoxia-induced factor (HIF), which induces the 
expression of a set of genes appropriate to respond to this situation. The 
classical paradigm is that of a change in cellular metabolism induced by HIF1 
in conditions of hypoxia, from aerobic metabolism to anaerobic pathways 
(Semenza 2012). HIF is not functional in oxygenated cells, but becomes 
active in the presence of hypoxic stress and in various other conditions, such 
as autocrine stimulation by growth factors or hormones. The target genes of 
HIF are involved in metabolism, erythropoiesis, pH homeostasis, and 
autophagy (Semenza 2012). Indeed, HIFα controls the expression of 
numerous major players involved in angiogenesis and vascular remodelling, 
including vascular endothelial growth factor (VEGF-A) and its receptor 
VEGFR1, CXCL12 (stroma-derived factor 1 or SDF-1), angiopoietin 2, 
platelet-derived growth factor (PDGF-BB), and SCF (stem cell factor) or c-Kit 
ligand. 
Mice constitutively expressing HIF1-α in cardiomyocytes display improved 
cardiac function after MI, associated with increased VEGF expression and 
angiogenesis in the myocardium (Kido, Du et al. 2005). The prominent role of 
the HIF pathway in post-ischemic angiogenesis has further been shown 
through its indirect activation by Prolyl Hydroxylase Domain proteins (PHDs). 
Oral administration of a PHD inhibitor in rats improved microvascular density 
in the peri-infarct area, preventing deterioration of cardiac function and left 
ventricle (Silvander, Kvarnstrom et al.) dilation after MI (Bao, Qin et al. 2010). 
In a model of hind-limb ischemia, knockdown of PHD enhanced 
neovascularization through upregulation of VEGF and endothelial Nitric 
Oxide Synthase (eNOS) as well as recruitment of proangiogenic myeloid 






1.2.2.2 Inflammation:  
The first evidence linking inflammation and angiogenesis was the expression 
of the proangiogenic Insulin Growth Factor-1 (IGF-1) by infiltrating monocytes 
in the ischemic porcine myocardium associated to capillary sprouting after 
microembolization (Kluge, Zimmermann et al. 1995). During ischemia, 
inflammatory cells release angiogenic factors, such as VEGF and TNF-α, 
that enhance vascular permeability and promote the recruitment of further 
inflammatory cells (Costa, Incio et al. 2007, Grivennikov, Greten et al. 2010, 
Eltzschig  and Carmeliet 2011, Konisti, Kiriakidis et al. 2012). Leukocytes and 
macrophages release matrix, among others, metalloproteinases (MMPs), 
plasminogen and cathepsins, that promote extracellular matrix (ECM) 
remodelling, favouring the formation of new vessels (Rüegg 2006, Kundu and 
Surh 2012). Neutrophils also release chemokines that enhance both, 
angiogenesis and inflammation (Kundu and Surh 2008, Noonan, De Lerma 
Barbaro et al. 2008). Finally, inflammatory cells produce Reactive Oxygen 
species (Masotti, Miller et al.) that act as a proangiogenic stimulus (Guzik, 
Korbut et al. 2003, Reuter, Gupta et al. 2010). 
Consistently with this relationship between angiogenesis and inflammation, 
different molecules that are relevant in inflammation have been involved in 
new vessel formation. For instance, monocyte chemoattractant protein-1 
(MCP-1) induces collateral growth after femoral artery occlusion in the rabbit 
(Ito, Arras et al. 1997). This effect is mediated by the attraction of monocytes 
and depends on the presence of Intercellular Adhesion Molecule-1 (ICAM-
1)(Hoefer, van Royen et al. 2004). Similarly, P-selectin is involved in 
angiogenesis, as P-selectin knockout mice show reduced reperfusion and 
less leukocytes expressing VEGF after hind limb ischemia (Egami, Murohara 
et al. 2006). Also, TNF-α enhances progenitor cell homing, VEGF and bFGF 
expression, and angiogenesis in mice hind limb ischemia (Kwon, Heo et al. 
2013) (Goukassian, Qin et al. 2007). Toll-like receptors (TLRs), that play a 
key role in innate immunity (Takeda and Akira 2004, Kawai and Akira 2006, 
Grote, Schütt et al. 2011), represent a clear example of the intersection 




(West, Malinin et al. 2010, Grote, Schütt et al. 2011) and have been 
implicated in angiogenesis, and in VEGF expression (Leibovich, Chen et al. 
2002, Pollet, Opina et al. 2003, Grote, Schuett et al. 2010, Paone, Galli et al. 
2010). 
There is also a synergy between the hypoxia pathway, controlled by HIF, and 
the induction and intensity of the inflammatory reaction, which is modulated 
principally by the transcription factor NF-κB. HIF-dependent hypoxic 
responses and the NF-κB-dependent inflammatory response are thus 
interdependent, and they amplify each other. Some inflammatory cytokines, 
including transforming growth factor (TGF)-β (McMahon, Charbonneau et al. 
2006) and interleukin (IL)-1β (Hellwig-Burgel, Rutkowski et al. 1999), may 
favour HIF-1 activity. Alternatively, the HIF pathway controls expression of 
the chemokine CXCL12, which plays a major role in the post-ischemic 









Figure 1.2: Mechanism of angiogenesis 
Shane P. Herbert & Didier Y. R. Stainier Nature Reviews Molecular Cell 
Biology volume 12, pages 551–564 (2011) 
   
	
	
1.2.3 Mechanisms of endothelial cell migration  
Endothelial cell migration in an angiogenic sprout is a guided and, therefore, 
directed process and guidance cues are provided by the local environment 
(Michaelis 2014).  
During sprouting angiogenesis, the previously described concept of tip and 
stalk cells is operative. The first step is, therefore, the selection of the cell 
that initiates sprout formation and becomes the tip cell. This is necessary 
because if all cells reacted in the same way to the stimulus, they would 
migrate in a similar manner and the vessel would disintegrate. Thus, only one 




entertained by VEGF and the Notch/Dll4 system (Hellstrom, Phng et al. 2007, 
Suchting, Freitas et al. 2007, Phng and Gerhardt 2009).  Endothelial cell 
polarization and hence the directionality of filopodia extension during 
migration is dependent on Cdc42 activation (Gerhardt 2008).  
Recently, the role for Hippo effectors YAP and TAZ in the regulation of 
vascular network remodelling through controlling ECs proliferation, filopodia 
formation, and cell migration has been characterized (Sakabe, Fan et al. 
2017). The study demonstrated that a novel cytoplasmic function of YAP in 
the regulation of ECs migration through controlling the Rho family GTPase 
CDC42 activity. Moreover, these findings demonstrated a previously 
unrecognized YAP/TAZ function involved in the vascular network remodeling 
during angiogenesis (Sakabe, Fan et al. 2017). 
The formation of branch-like filopodia by tip ECs is mediated by remodelling 
of the actomyosin and microtubule cytoskeleton, similar to the way in which 
neurite extensions protrude from neuronal cell bodies (Gerhardt, Golding et 
al. 2003). The formation of endothelial branches from lamellipodia has been 
described to be dependent on the local attenuation of myosin II-mediated 
contraction. The process is a consequence of a local loss of RhoA and RhoA 
kinase (ROCK) activity leading to reduced myosin light-chain 
phosphorylation. As a consequence, the cell branches by ‘‘escaping’’ 
retraction through cortical tension (Fischer, Gardel et al. 2009).  
 
1.2.4 Endothelial dysfunction and vascular disease 
Under basal conditions, the endothelium functions to maintain the vessel in a 
relatively neutral state favouring dilatation over constriction. The endothelial-
dependent response to vasodilate is principally regulated in response to 
shear stress by a release of nitric oxide (NO) synthesized from the amino 
acid L-arginine by endothelial nitric oxide synthase (eNOS) (Vanhoutte, 
Shimokawa et al. 2017). Dysfunctional endothelium is seen when there is an 
imbalance between NO production and consumption.  Such a pathologic 
state creates favourable conditions for platelet plus leukocyte activation and 




of the vessel wall to oxidized lipoproteins and inflammation mediators, finally 
resulting in structural damage of the arterial wall with smooth muscle (SMC) 
cell proliferation and atherosclerotic plaque formation (Vanhoutte, 
Shimokawa et al. 2017). 
Abnormal endothelial function is attributed to high oxidative stress and 
inflammation – both processes lead to abnormal NO metabolism. Increased 
oxidative stress is characterized by a measurable increase in reactive oxygen 
species (Masotti, Miller et al.) which can result from impaired NO synthase, 
decreased L-arg uptake, increased oxidized LDL cholesterol (Ox-LDL), 
(Vergnani, Hatrik et al. 2000) or reduced superoxide dismutase (SOD) an 
enzyme pivotal in the clearing of ROS (Landmesser, Spiekermann et al. 
2002).  Another potential contributor to impaired NO bioavailability is the 
decrease in tetrahydrobiopterin (THB)(Li, Chen et al. 2011) or the presence 
of elevated levels in plasma of asymmetric dimethylarginine (ADMA), which 
is an endogenous competitive inhibitor of NO  (Boger, Lentz et al. 
2001).37,38  Finally, low-flow vascular states such as reduced cardiac output 
which reduces endothelial shear stress in conditions such as heart failure – 
possibly from reduced L-arginine (Hingorani, Cross et al. 2000).  
Endothelial dysfunction is seen in patients with a family history of early 
cardiovascular disease and other risk factors such as hypertriglyceridemia 
(Lundman, Eriksson et al. 2001), elevated LDL and reduced HDL cholesterol 
(Ford, McConnell et al. 2009), nicotine use (Lavi, Prasad et al. 2007),10 
obese patients with minimal coronary artery disease (CAD) (Al Suwaidi, 
Higano et al. 2001), patients with insulin resistant (Arcaro, Cretti et al. 2002) 
and elderly patients (Egashira, Inou et al. 1993).  
The true prevalence of peripheral endothelial function worldwide is not fully 
known as I only have samples of larger studies which assess peripheral 
endothelial function in different methods and without specific guidelines 
regarding cut-off values for which a patient's endothelium is considered 
dysfunctional. Observations demonstrated that roughly 50% of those 




disease were found to have coronary endothelial dysfunction (Sharaf, Pepine 
et al. 2001). 
The quantification of endothelial health has commonly been divided into 
peripheral endothelial function – a systemic measure of endothelial function – 
versus coronary endothelial function, which must be assessed with invasive 
angiography. Testing involves pharmacological and/or physiological 
stimulation of the endothelial release of NO and other vasoactive substances. 
All the techniques have in common that they measure the response of the 
vessels to endothelial-dependent stimuli, mainly reactive hyperemia or 
vasoactive substances. Indeed, both macrovascular endothelial dysfunction, 
as measured by flow-mediated dilation (Yeboah, Folsom et al. 2009) and 
microvascular endothelial dysfunction (Anderson, Charbonneau et al. 2011), 
have been found to be independent predictors of future cardiovascular 
events in large cohort studies in healthy individuals over and above 
traditional risk factor assessment.  
 
1.2.5 Mitochondrial function in vascular disease 
In comparison with other cell types with higher energy requirements, 
mitochondria content in ECs is modest and it composes 2–6% of the cell 
volume as opposed to 28% in hepatocytes and 32% in cardiac myocytes 
(Dromparis and Michelakis 2013). The low content of mitochondria in ECs 
may indicate that mitochondria-dependent oxidative phosphorylation is not 
that important for energy supplement in those cells. In fact, ECs obtain a 
large proportion of their energy from the anaerobic glycolytic metabolism of 
glucose. Mitochondria are more likely to serve primarily as essential signaling 
organelles in the vascular endothelium (Quintero, Colombo et al. 2006). 
The cellular distribution of mitochondria is important for its function and its 
communication with another cellular organelle (especially endoplasmic 
reticulum, ER) and nucleus. For example, in ECs of arterioles isolated from 
human myocardium, mitochondria are anchored to the cytoskeleton. Those 
mitochondria release ROS in response to cell deformation by shear stress. 




triggers a retrograde mitochondrial movement that requires microtubules and 
the microtubule motor protein dynein, resulting in the perinuclear clustering of 
mitochondria. This subcellular redistribution of mitochondria is accompanied 
by the accumulation of ROS in the nucleus, which can be attenuated by 
suppressing perinuclear clustering of mitochondria with nocodazole to 
destabilize microtubules (Al-Mehdi, Pastukh et al. 2012). Mitochondria are 
important component of the intracellular Ca2+ signaling and buffering system, 
played in tight functional and physical association with ER. For example 
mithocondria and ER distance seems to be critical for Ca2+ driven 
mitochondrial dependent apoptosis in EC during Peripheral Artery 
Hypertension (PAH)(Sutendra, Dromparis et al. 2011). 
Endothelial mitochondria serve as a pivotal sensor of the local environment 
and transduce damage signals, which leads to mitochondria damage, 
endothelial dysfunction, vascular remodelling and vascular diseases (Tang, 
Luo et al. 2014).  
Over the last decade, accumulating evidence has suggested a causative link 
between mitochondrial dysfunction and major phenotypes associated with 
endothelial senescence (Ziegler, Wiley et al. 2015). EC senescence is 
associated with impaired mitochondrial biogenesis, reduced mitochondrial 
mass and altered expression of components of the ETC and other 
mitochondrial components (Dai, Rabinovitch et al. 2012). Mitochondrial 
superoxide production increases with replicative senescence. Damaged 
mitochondria produce excessive superoxide and H2O2, which are major 
determinants of telomere-dependent senescence at the single-cell level that 
is responsible for cell-to-cell variation in replicative lifespan (Passos, Saretzki 
et al. 2007). 
Dysfunction of the ETC critically participates in endothelial senescence. 
Deficiency of mitochondrial ETC complex IV plays an essential role in 
senescence-induced mitochondrial dysfunction.	 Mitochondria of senescent 
HUVECs show a significant and equal decrease in both fusion and fission 




contribute to the accumulation of damaged mitochondria during aging 
(Jendrach, Pohl et al. 2005) 
Decreased expression of Drp1 and Fis1, two proteins regulating 
mitochondrial fission, mediates mitochondrial elongation in senescent cells 
(Mai, Klinkenberg et al. 2010). Loss of mitochondria dynamics and 
mitochondrial potential are associated with increased ROS production and 
mtDNA damage and decrease mitochondria biogenesis and NO production in 
cultured ECs (Mai, Klinkenberg et al. 2010). High glucose and continuous 
oxidation of high density lipoprotein (HDL) under hyperglycemic condition 
induce mitochondrial dysfunction and EC apoptosis through mitochondrial 
fission and mitochondrial and cytosolic ROS generation (Matsunaga, Iguchi 
et al. 2001). Dysfunctional mitochondria are isolated from the mitochondrial 
network and are eliminated by selective type of autophagy called mitophagy. 
PINK and PARKIN are part of a well known mitochondrial quality control 
mechanism able to sense loss in mitochondrial potential, lipid and protein 
peroxidation and protein ubiquitination on the surface of damage 
mitochondria. Mitophagy is an important response to restrain excessive 
mROS production and its role in the surveillance and maintenance of 
functional mitochondria is highlight by the fact that many cardiovascular 
pathologies including diabetes mellitus, atherosclerosis and hypertensive 
heart shown impaired mitophagy. (Mai et al.,2012; Higdon et al.,2012). 
Moreover mitochondrial ROS in particular H2O2 are positive inducers of 
autophagy during environmental stress condition like hypoxia or starvation 
(Scherz-Shouval, Shvets et al. 2007). 
 
 
1.2.6 Vascular senescence 
Aging is a known major risk factor for cardiovascular disease (Niccoli and 
Partridge 2012). The aging process is also associated with adverse 
hemodynamic and metabolic changes that accelerate the development of 
cardiovascular disease. It is now accepted that changes in cardiovascular 




alterations precede the onset of clinical disease and predict the future risk of 
developing atherosclerosis, hypertension and heart failure (North and Sinclair 
2012). The age-associated changes in blood vessels that occur in healthy 
individuals include increased arterial wall thickness, luminal dilatation and 
reduced compliance (Minamino and Komuro 2008). In addition to these 
structural changes, endothelial function becomes impaired with increasing 
age, thereby increasing arterial stiffness. Aged ECs develop a dysfunctional 
phenotype that is characterized by reduced proliferation and migration, less 
expression of angiogenic molecules, and low production of nitric oxide (NO). 
Moreover, dysfunctional/senescent ECs develop pro-oxidant, pro-
inflammatory, vasoconstrictor, and prothrombotic properties. Moreover, 
evidence indicates that cardiovascular repair systems become progressively 
impaired with aging (Lakatta 2003, Lakatta and Levy 2003, Lakatta and Levy 
2003).  
These impairments are attributed to the reduced production of proangiogenic 
factors (Fontana, Vinciguerra et al. 2012), impaired cell replication (de 
Almeida, Ribeiro et al. 2017), and a decrease in the number and function of 
stem and/or progenitor cells (Zhuo, Li et al. 2010, Cesselli, Aleksova et al. 
2017). Even if these age-associated changes do not result in overt 
cardiovascular disease per se, they impair the capacity of the cardiovascular 
system and influence the severity and prognosis of subsequent disease. A 
senescent endothelial cell presents senescence-associated morphological 
alterations and functional adaptations, like senescent fibroblast 
(Unterluggauer, Hutter et al. 2007) .  Most commonly, senescence-
associated beta-galactosidase (SA-β-gal) activity is used to identify 
senescent cells. Lysosomal beta-galactosidase activity is normally detected 
at a low pH (usually pH 4), but becomes detectable at a higher pH (pH 6) in 
senescent cells due to marked expansion of the lysosomal compartment 
(Dimri, Lee et al. 1995).  Cellular senescence is associated with the 
acquisition of the Senescence-Associated Secretory Phenotype (SASP), 
which is characterized by the activation of a pro-inflammatory transcriptional 




recent hypothesis, the build-up of cells expressing the SASP may promote 
the development of both diabetes and its vascular complications (Childs, 
Durik et al. 2015, Palmer, Tchkonia et al. 2015).  
Cellular and molecular mechanisms underlying age-associated changes of 
the cardiovascular system have been studied, but it remains unclear exactly 
how these alterations occur with advancing age. Interestingly, the main 
pathways involved in cellular senescence regulation, such as the NF-κB, the 
mechanistic target of rapamycin (mTOR), and the interleukin-1/NLR family 
pyrin domain containing 3 (IL-1/NLRP3) inflammasome pathways, are master 
modulators of the aging rate (Johnson, Rabinovitch et al. 2013, Youm, Grant 
et al. 2013, Zhang, Li et al. 2013).  A number of adaptor proteins have been 
shown to control SASP factor secretion. The SASP is mostly induced by NF-
𝜅B, the main immunological transcription factor (Chien, Scuoppo et al. 2011). 
Upstream, p38 (Freund, Patil et al. 2011), JAK (Xu, Tchkonia et al. 2015), 
and other MAP kinases (Ferrand, Kirsh et al. 2015), are all involved in SASP 
induction and control. Interestingly, Jak2/Stat3 pathway inhibition redesigns 
the SASP, suppressing the secretion of certain factors indicating that 
selective SASP modulation could be feasible (Toso, Revandkar et al. 2014). 
Finally, highly interesting results in terms of SASP suppression have been 
obtained with the mTOR inhibitor rapamycin (Laberge, Sun et al. 2015), 
which has long been known to extend lifespan and health span in mice 
(Laberge, Sun et al. 2015). mTOR controls SASP protein secretion by 
enhancing IL-1𝛼 and MAP kinase activated protein kinase 2 (MAPKAP2) 
translation (Herranz, Gallage et al. 2015). 
Interventions directed at preventing the adverse effects associated with the 
SASP are being explored. The most promising strategies involve delaying 
cellular senescence (Jurk, Wilson et al. 2014); SASP switch-off (Herranz, 
Gallage et al. 2015); SASP factor modulation (Toso, Revandkar et al. 2014); 
and selective removal or killing of existing senescent cells (Chang, Wang et 
al. 2016). Selective targeting and killing of senescent cells without damaging 
neighbouring, healthy cells requires identifying senescence-associated 




metabolomics, metagenomics, and transcriptomics) are being applied to 
discover such markers (Valdes, Glass et al. 2013). Highly promising results 
are coming from work on SASP suppressor and senolytic agents (Childs, 




Figure 1.4: Senescence as a central hallmark of aging.  
Graphical summary of the main causes leading to senescence and effects 
senescent cells produce in the surrounding tissue. 







1.3.1 Definition of autophagy   
Autophagy is a complex intracellular process that delivers cytoplasmic 
constituents for degradation into lysosomes. Three main types of autophagy 
have been described: microautophagy (Mizushima and Komatsu 2011), 
comprising direct engulfment of cytoplasmic material by lysosomes via 
inward invaginations of the lysosomal membrane, macroautophagy (Feng, 
He et al. 2014), characterized by formation of double-membrane 
sequestering compartments termed autophagosomes that fuse with 
lysosomes for delivery of cytoplasmic cargo, and chaperone-mediated 
autophagy (Klionsky, Abdalla et al. 2012), mediated by a chaperone complex 
and lysosomal-associated membrane protein type 2A to degrade cytosolic 
proteins with a specific targeting motif. Autophagy occurs at basal levels in 
most tissues to allow constitutive turnover of cytosolic components but is 
stimulated by environmental stress-related signals (eg, nutrient deprivation 
and oxidative injury) to recycle nutrients and to generate energy for 
maintenance of cell viability in adverse conditions (Klionsky, Abdalla et al. 
2012). In addition to cellular stress, basal autophagy can be intensified by 
specific drugs, indicating that the autophagic machinery is a potential 
therapeutic target for diverse diseases. Indeed, given that autophagy is 
involved in the prevention of different human pathological conditions, 
including heart and liver disease, cancer, neurodegeneration, as well as 
infectious and metabolic disorders, the development of highly specific 







Figure 1.3: Mechanisms of autophagy  
A simplified and schematic view of the main steps occurring during 
Macroautophagy.  




1.3.2 Regulation of autophagy 
One of the major regulators mTOR, an evolutionarily conserved 
serine/threonine kinase, which integrates metabolic signals including amino 
acids and growth factors as well as oxygen and energy level to coordinate 
cell growth, proliferation, and metabolic processes to maintain cellular 
homeostasis. mTOR forms two complexes with distinct functions, but only 
mTOR complex 1 (mTORC1) has been described in the regulation of 




induction by phosphorylating the initiation complex members (Meijer, Lorin et 
al. 2015) 
TORC1 activity is regulated by multiple signalling pathways and molecules. 
Upon receptor tyrosine kinase activation in the presence of insulin-like and 
other growth factors, the serine/threonine kinase AKT phosphorylates and 
thus inhibits tuberous sclerosis complex (TSC1/TSC2), a GTPase-activating 
protein (GAP) for the small GTPase Rheb  (Zhang, Gao et al. 2003). 
Consequently, Rheb is stabilized in an active, GTP-bound form and activates 
mTORC1, thereby repressing autophagy (Long, Ortiz-Vega et al. 2005). 
Subcellular localization of mTORC1 has an essential role in its regulation, as 
well. Amino acid sufficiency promotes the activation of RAG GTPases in a 
Ragulator complex-dependent manner (Sancak, Bar-Peled et al. 2010).  
5′-AMP-activated protein kinase (AMPK), activated upon low cellular energy 
levels, regulates autophagy positively both by direct phosphorylation of ULK1 
and indirectly by repressing mTORC1 activity (Bach, Larance et al. 2011). 
Autophagy regulation is not confined to the modulation of the induction. Upon 
hypoxia, HIF1α transcription factor activates expression of several genes 
necessary for metabolic adaptation to low oxygen levels. Among these 
hypoxia responsive genes, there are BNIP3 and BNIP3L, which were found 
to increase mitochondrial autophagy (Ney 2015). Among others, the ER-
associated IP(3) receptor functions as an autophagy inhibitor by forming a 
complex with BECN1 and probably Bcl-2  (Vicencio, Ortiz et al. 2009). In 
addition, upon nutrient starvation, c-Jun N-terminal protein kinase 1 (JNK1) 
contributes to the induction of autophagy by phosphorylating Bcl-2 and 
thereby disrupting its interaction with BECN1 (Wei, Pattingre et al. 2008) 
Oxidative stress promotes autophagy in another VPS34-dependent manner 
as well. Under these conditions, death-associated protein serine/threonine 
kinase (DAPK), a well-known regulator of cell death activates protein kinase 
D (PKD), which subsequently phosphorylates VPS34 leading to increased 








1.3.3 Autophagy in ECs 
There is a growing body of literature that suggests that loss of autophagy 
may be a central mechanism through which risk factors elicit endothelial 
dysfunction, and that autophagy may be involved in the regulation of nitric 
oxide (NO) bioavailability. 
For example, in ECs, shear stress–induced increases in endothelial nitric 
oxide synthase (NOS3) phosphorylation and NO production are markedly 
blunted in autophagy-deficient cells. Coincident with a reduction in NO, loss 
of autophagy promotes an increase in endothelial reactive oxygen species 
(Masotti, Miller et al.) and inflammatory cytokine production, suggesting that 
autophagy may regulate shear stress–induced vascular homeostasis, in part, 
through an NOS3-dependent pathway (Bharath, Mueller et al. 2014). These 
data have recently been confirmed using an ex vivo model of steady laminar 
shear stress, wherein autophagy inhibition (with 3-methyladenine) inhibits 
NOS3 expression, whereas autophagy stimulation (with rapamycin) 
increases endothelial NOS3 expression (Guo, Li et al. 2014). Emerging 
evidence also suggests that endothelial autophagy might modulate the 
uncoupling of NOS3 (with an increase in superoxide versus NO production). 
Similarly, recent data also suggest an important role of intracellular NO in the 
regulation of mitophagy, the selective process involving autophagic 
degradation of mitochondria.  
A link between endothelial autophagy and angiogenesis comes from the 
analysis of mice deficient in AKT3. These animals have an impaired 
angiogenic response using a standard subcutaneous Matrigel plug assay. 
This same study also demonstrated that knockdown of AKT3 induces 
autophagy in ECs. Interestingly, this induction seemed to be independent of 
MTOR (a known AKT substrate and target) and instead dependent on 
XPO1/CRM1 (exportin 1/CRM1 homolog yeast), the major nuclear export 









1.3.4 Autophagy as therapeutic target in vascular diseases 
Considerable enthusiasm has emerged for the development of autophagy-
inducing agents for the prevention or treatment of diseases in which the 
upregulation of autophagy is thought to be clinically beneficial (Levine, 
Packer et al. 2015). Several drugs currently approved by the FDA induce 
autophagy but generally have pleiotropic actions, making it difficult to parse 
out the role of autophagy induction in their therapeutic actions in patients. 
Nonetheless, preclinical studies demonstrate that certain autophagy-inducing 
agents fail to induce their beneficial effects in host organisms that are 
deficient in autophagy genes (Rubinsztein, Codogno et al. 2012). 
FDA-approved compounds have been “repurposed” for use in preclinical 
models of diseases that are believed to respond favourably to autophagy 
enhancement, e.g., mTOR inhibitors in neurodegenerative diseases, EGFR 
and other tyrosine kinase inhibitors in diabetic nephropathy (Sarkar 2013). 
Several drugs that have the potential to inhibit or stimulate autophagy have 
already been identified, and now ongoing clinical trials are testing their 
association with cytotoxic drugs in a variety of cancers (Towers and Thorburn 
2016).  
Activators of autophagy, for instance, rapamycin and its derivatives 
(everolimus) that trigger autophagy through the inhibition of mTOR have 
been evaluated as potential plaque stabilizing drugs. Local stent-based 
delivery of everolimus in atherosclerotic plaques from cholesterol-fed rabbits 
led to a striking reduction in macrophage content without altering SMCs 
(Vicencio, Ortiz et al. 2009).   
Carbamazepine, valproic acid increases the intracellular clearance of 
misfolded protein accumulation through induction of autophagy by reducing 




Interestingly, stimulation of autophagy by valproic acid decreases 
calcification by reducing matrix vesicle release in vascular SMCs (Dai, Zhao 
et al. 2013). Additionally, using a cell-based screening method, several 
calcium channel blockers and antiarrhythmic drugs, such as verapamil, 
loperamide, amiodarone, nimodipine, nitrendipine, niguldipine and pimozide, 
have been identified as autophagy inducers by inhibiting intracellular levels of 
calcium (Fleming, Noda et al. 2011) 
The pan-caspase inhibitor benzyloxycarbonyl-Val-Ala-DL-Asp(O-methyl)-
fluoromethylketone (z-VAD-fmk) can induce autophagy and necrotic cell 
death in macrophages and, indirectly, necrosis of vascular SMCs based 
mainly on the differential expression of receptor-interacting protein 1 
(Martinet, Schrijvers et al. 2006). Trehalose, a disaccharide, enhances the 
clearance of autophagy substrates (Sarkar, Davies et al. 2007) . Trehalose 
supplementation restores the expression of autophagy markers and rescues 
vascular endothelial function by increasing NO bioavailability, reducing 
oxidative stress and normalizing inflammatory cytokines in arteries of ageing 






1.4 Hypothesis  
The hypothesis addressed in this Thesis is:  




To address this hypothesis, experiments have been designed to determine 
whether: 
1. TCHP regulates EC function. 
2. TCHP regulates autophagic flux and senescence in ECs 



































Cell lines and cell culture 
Human cell lines were the experimental model used in this study. HEK293T 
were grown in Dulbecco’s modified eagle’s medium (DMEM), BE12-741F, 
with 4.5g/L glucose, 2mM L-Glutamine, without Na Pyruvate manufactured 
by Lonza. 10% v/v Fetal bovine serum (FBS) and 1% v/v 
Penicillin/Streptomycin (Pen/Strep) were added to make complete media. 
HUVECs were the predominant in vitro model used in this study. HUVEC, 
catalogue number (cat#) C2519A, lot number (lot#) 0000466716 purchased 
from Lonza were cultured in endothelial basal media-2 (EBM™-2) purchased 
in the form of SingleQuots™ Kit, CC-4176, containing all supplementary 
growth factors required.   
 
Endothelial cells from patients 
The study was performed with the approval of the South-East Scotland 
Research Ethics Committee, in accordance with the Declaration of Helsinki 
and with the written informed consent of all participants. Patients with 
premature coronary artery disease and a family history of premature 
coronary artery disease (n = 8) were identified from the outpatient 
department, Royal Infirmary of Edinburgh, Scotland, UK. A control group of 
healthy age- and sex-matched subjects (n = 8) with no evidence of 
significant coronary artery disease following computed tomography coronary 
angiography (CTCA) was recruited from the Clinical Research Imaging 
Centre, Royal Infirmary of Edinburgh. Subjects attended the Clinical 
Research Facility at the Royal Infirmary of Edinburgh for vascular 
assessment and tissue sampling. Vessel wall endothelial cells were isolated 
by wire biopsy for in vitro expansion(Brittan, Hunter et al. 2015). 
 
Lentiviral vectors 
Two pLKO based, self-inactivating lentiviruses, able to infect mammalian 
cells lines, were produced for this study. One lentivirus vector was produced 




specifically targeting TCHP mRNA transcripts. A control lentivirus encoding a 
scrambled shRNA sequence was also produced. The pLKO DNA plasmid 
containing the shRNA sequence against human TCHP, was purchased from 
Sigma Aldrich Mission®RNAi team, product code TRCN0000127662. The 
scramble sequence shRNA plasmid was purchased from Addgene, plasmid 
#1864. Lentiviral vectors were produced by the Biomolecular Core of the 
Shared University Research Facilities at Edinburgh University. The packing 
plasmids used were pCMV-dR8.2 dvpr, plasmid #8455 from Addgene, and 
pCMV-VSVG, plasmid #8454 from Addgene respectively. HUVECs were 





Impedance based scratch assays and barrier functions 
experiments 
Electric Cell-substrate Impedance Sensing (ECIS) is an in vitro impedance 
measuring system to quantify the behavior of cells within adherent cell layers. 
Migration assay and endothelial barrier function were performed using ECIS 
machine using 8W1LE and 8W10E array, respectively. 60,000 cells are 
grown on the arrays on top of opposing, circular gold electrodes. A constant 
small alternating current is applied between the electrodes and the potential 
across is measured. The insulating properties of the cell membrane create a 
resistance towards the electrical current flow resulting in an increased 
electrical potential between the electrodes. The basis for the measurement of 
the electrical impedance of cells is Ohm's law, a basic electro-technical 
principle, which describes the relation between resistance (R), current (I) and 
voltage (U) in an electrical circuit at a given time (t). For the barrier function, 
the cell monolayer are stimulated with 20 ng/ml of VEGF and impedance is 
record for 24 hrs. For the migration, the gap in the monolayer is performed 
increasing the voltage on the electrodes. Speed is determined as the time the 





Total protein extraction and quantification  
Cells were rinsed once with ice-cold PBS when still in the plate, lysed with 
RIPA lysis buffer (20 mM Tris-HCl (pH 7.5),150 mM NaCl, 1 mM Na2EDTA, 1 
mM EGTA, 1% NP-40, 1% sodium deoxycholate, 2.5 mM sodium 
pyrophosphate, 1 mM β-glycerophosphat, 1 mM Na3VO4, 1 µg/ml leupeptin 
and one tablet of EDTA-free protease inhibitor [Roche] per 10 ml) and 
collected in a tube using scrapers. The tubes contening the cells suspension 
were left 20 minute on ice to let the lysis complete and centrifuged at 13.000 
r.p.m. in order to separate the cell lysate to the insoluble membranes. The 
Pierce™ BCA protein determination method was used to quantify the total 
amount of protein in order to load both SDS-PAGE and Native-PAGE gels. 
All protein determination assays were performed using the Pierce™ BCA 
protein assay kit cat# 3225 from Thermo Fisher Scientific. Protein 
determinations were performed according to the manufacturer’s instructions. 
Briefly, 3 or 5 µl of the unknown samples are placed in the wells of a 
Microplate and then mixed with 200µl of working reagent made of 50:1 ratio 
of BCA Reagent A (sodium carbonate, sodium bicarbonate, bicinchoninic 
acid and sodium tartrate in 0.1M sodium hydroxide) and BCA Reagent B (4% 
cupric sulphate). After an incubation at 37 degrees for a variable period of 
time (usually between 30min to 2 hours) depending on the amount of 
proteins present in the samples, the absorbance for each samples and the 
standard curve was read at 562 nm with a standard platereader. The protein 
concentration was derived interpolating the 562nm absorbance value of each 
unknown samples with the absorbance values of known concentrations of a 
BSA standard curve. Usually 10 or 20 µg of proteins for samples were used 
for subsequent Western Blot application. 
 
Western blot 
Western blot was performed to assess protein expression levels. Sodium 




using variable acrylamide percentage gels were prepared using Bio-Rad 
Mini-Protean® Tetra hand cast system. Standard compounds used; ProtoGel 
30% (w/v) Acrylamide:0.8% (w/v) Bis-acrylamide stock (37.5:1), National 
diagnostics. TEMED, Cat# 161-0800, Bio-Rad. SDS, L4390-500g, Sigma 
Aldrich. Samples were treated by addition of Laemmli buffer 2x (65.8 mM 
Tris-HCl pH 6.8, 26.3% (w/v) glycerol, 2.1% SDS,0.01% bromophenol blue) 
in a 1:1 ratio to sample. The treated samples were incubated for 5 min at 
100°C and cooled to 4 C0 before loading. The electrophoresis was performed  
submerging the gel in a standard migration buffer (also called running buffer) 
for PAGE is 1X Tris-glycine Buffer pH 8.3 (25 mM Tris base,190 mM 
glycine,0.1% SDS). Equal amounts of proteins were loaded onto SDS-
Polyacrilamide gels and transferred to Amersham™ Hybond™ 0.2µm 
polyvinylidene difluoride (PVDF) blotting membrane which was pre-activated 
with methanol. Mini Trans-Blot® cells were used to transfer proteins from 
gels to PVDF. The membranes were then blocked with 5% non-fat milk in 
TBST 0,1% and immunoblotted overnight at 4°C with different primary 
antibodies listed in the WB table together with their working dilutions. 
Chemiluminescent detection of proteins of interest was achieved using 
Immobilon™ Western Chemiluminescent HRP Substrate kit, WBKLS0500 
manufactured by Millipore. Kit used as per the manufacturer’s instructions. 
The Western blots were developed on X-ray film using a Konica Minolta 
SRX-101A medical x-ray film processor. Pixel intensity/quantification was 
performed using ImageJ. 
 
Table 1: Primary and secondary antibodies used for western blotting 
including manufacturer details and titers used. 
































– raised in mouse, 
monoclonal 
Abcam/MitoProfiler®Total OXPHOS Blue 
Native WB antibody cocktail MS603-300, 







GeneTex, GTX100685-S 1:1000 
LC3B rabbit 
polyclonal IgG 









XP® Rabbit mAb 

















DB Bioscience 551154 1:250 
PARP1 policlonal 
anti Rabbit  
 





(10H) Mouse IgG 
MoAb 








Native-PAGE of mitochondrial electron chain complexes 
To assess the effect of TCHP knock-down on the electron transport chain 
(ETC) also referred to as OXPHOS complexes, Native-PAGE was used to 
separate the different complexes while in their native conformation followed 
by western blotting. All products were used according to manufacturer’s 
instructions. The Novex® NativePAGE™ Bis-Tris gel system purchased from 
Thermo Fisher Scientific was used to separate the mitochondrial electron 
chain complexes. Kit included Invitrogen NativePAGE™ 3-12% Bis-Tris Gels, 
cat# BN1001BOX. NativePAGE™ 20X Cathode Buffer Additive, cat# 
BN2002, lot# 1772846. Native-PAGE™ 20X Running Buffer, cat# BN2001, 
lot# 1772822. As well as NativePAGE™ Sample Prep Kit, cat# BN008, lot# 
1772859. 
 
Mitochondrial isolation protocol 
In order to separate OXPHOS complexes using Native-PAGE, mitochondria 
were isolated from control and TCHP know-down HUVECs. The 
mitochondrial isolation protocol used by (Frezza et al. 2007) to isolate mouse 
embryonic fibroblasts (page 289) was used as a starting point to develop the 
Secondary 
Antibodies 
Manufacturer details Titer 
Anti-rabbit IgG A0545 Sigma - Anti-Rabbit IgG (whole 
molecule)–Peroxidase antibody produced 
in goat, lot # 054M4812 
 
1:10000 
Anti-mouse IgG A5906 Sigma - Anti-Mouse IgG (whole 
molecule)–Peroxidase antibody produced 






protocol in HUVECs. Cells were harvested and suspended in ice cold IBc 
buffer (10 ml of 0.1M Tris-MOPS, 1 ml of EGTA/Tris, 20 ml 1M sucrose made 
to 100 ml in DH2O, pH = 7.4, Complete™ protease inhibitor added). Cells 
were then homogenised using a Teflon pestle. A number of centrifugation 
steps followed in order to isolate the mitochondria from the homogenate. 	
 
Solubilisation of mitochondria 
Mitochondria isolates were solubilised as per the manual provided with the 
Native-PAGE system. Digitonin detergent provided in the sample prep kit 
was used at a final concentration of 2.5% v/v which was found to yield the 
best solubilization results.  
 
Running Native-PAGE gels 
Invitrogen NativePAGE™ 3-12% Bis-Tris Gels were loaded and run 
according to the manufacture’s kit instructions. The gels were transferred 
onto PVDF membrane for western blotting and subsequent western blot pixel 
quantification using UN-SCAN-IT gel version 6.1.  
 
Seahorse: Mitochondrial respiration stress test 
The Seahorse XFe24, Extracellular Flux analyzer manufactured by Agilent 
Technologies was used to conduct a mitochondrial stress test to quantify key 
parameters of mitochondrial respiration under control and TCHP know-down 
conditions. The test included injecting predetermined volumes of a number of 
drugs onto cells and measuring oxygen consumptions throughout the time 
course. 
 
Cell preparation for Seahorse 
Control HUVECs and TCHP know-down were plated into Seahorse XF24 V7, 




either day three and seven days after infection. Cells were washed three 
times with fresh culture media just prior to analsysis on the Seahorse system. 
 
Seahorse Bio-analyzer XF Cell Mito Stress Test protocol 
The Seahorse XF cell Mito Stress Test was performed on cell preparations 
using the Seahorse XFe24, Extracellular Flux analyzer. Cell were analyzed 
four and seven days after infection. Results shown for each day represent 
the data from individual Seahorse XF24 V7, 24 well microplates.  
 
Flow cytometry 
Both control and TCHP know-down cells were analyzed to determine total 
mitochondrial mass and relative levels of mitochondrial ROS. 
Table 2: Fluorescent probes used to quantify mitochondrial mass and 
mitochondrial ROS. 
Probe used in flow cytometry Manufacture Final conc. used 
MitoTacker®Green FM – 









H2XRos – Mitochondrial ROS 








Probes were incubated with cells for 30 minutes at 36°C prior to washing with 
PBS and subsequent detachment with trypsin before being analysed. A BD 
LSR Fortessa (5 laser) flow cytometry analyser was used for all flow 
cytometry experiments. A minimum of 10000 total events per sample 






Cells were grown directly on glass slides previously coated with 10µg/ml 
Fibronectin and 0.2% gelatin from porcine skin (Sigma G1393. At the 
appropriate time cells were washed twice with 1X PBS and fixed with4% 
formaldehyde (Alfa Aesar #43368) for 30 minutes at room temperature. After 
carefully washed 2 times with PBS cells were permeabilized with 
Permeabilizing Solution (0.5% Triton X-100, 3 mm EDTA, pH 8.0 in Assay 
Beffer 1x) on ice, and gently shake for 30 minutes. Cells were then washed 
twice with 1X PBS and incubated with Dual Detection Reagent (1 µL of 
PROTEOSTAT® Aggresome Detection Reagent and 2 µL of Hoechst 33342 
Nuclear Stain in 2ml of 1x Assay Buffer) for 30 minutes at room temperature 
protected from light. Carefully the cells were washed other 3-4 times with 1X 
PBS and the coverslips were mounted with 20 µl of Fluoromount-GR 
(SouthernBiotech#0100-01) on a microscope slide. Cells were analysed by 
wide-field fluorescence or confocal microscopy using a standard rhodamine 
filter set for imaging the cell aggresome signal and a DAPI filter set for 
imaging the nuclear signal.  
 
Immunofluorescence  
80,000 HUVECs cells were plated on fibronectin-coated glass coverslips in 
24-well tissue culture plates. Twenty-four hours later, the slides were rinsed 
with PBS once and fixed for 15 min with 4% paraformaldehyde in PBS at 
room temperature. The slides were rinsed twice with PBS and cells were 
permeabilized with 0.05% Triton X-100 in PBS for 5 min. After rinsing twice 
with PBS, the slides were incubated with primary antibody in 3% BSA O.N. in 
a cold room, rinsed four times with PBS, and incubated with secondary 
antibodies diluted 1:1000 in 3% BSA for 45 min at room temperature in the 
dark and washed four time with PBS. Slides were mounted on glass 
coverslips using Vectashield (Vector Laboratories) and imaged on Zeis LSM-




with a Photometrics® coolSNAP HQ2 CCD camera and QImaging® CRI 
Micro*Color 2 RGB Liquid Crystal Tunable Filters were used to image 
fluorescently stained microtubules.  
 
Table 3: Primary and secondary antibodies used for immunofluorescence 
including manufacturer details, and titers used 




GeneTex, GTX100685-S 1:1000 
LC3B rabbit 
polyclonal IgG 
Cell Signalling, CS 2775s 1:2000 
Tom20 mouse 
monoclonal IgG 
Santa Cruz BiotechnologySC-17764  
1:2000 
Caveolin-1 (D46G3) 
XP® Rabbit mAb 
Cell Signalling, 3267 1:1000 
Clathrin Heavy 
Chain (D3C6) XP®  
Cell Signalling,	4796 1:1000 
Rabbit mAb Rab5 
(C8B1) Rabbit mAb 
Cell Signalling,3547 1:1000 
Rab11 (D4F5) XP® 
Rabbit mAb 
Cell Signalling,5589 1:1000 
EEA1 (C45B10) 
Rabbit mAb 
Cell Signalling,3288 1:1000 
Rab7 (D95F2) XP® 
Rabbit mAb 
Cell Signalling,9367 1:1000 
TFEB policlonal anti 
Rabbit 
GeneTex, GTX33541 1:1000 
Texas Red™-X 
Phalloidin 
Molecular probes T7471 1:1000 
 
Secondary Manufacturer details Titer   
Alexa-Fluor ® 555 
Goat anti-Rabbit 
IgG (H+L) 
Molecular probes A32727 1:1000 
Alexa-Fluor ® 
488\ Goat anti-
Rabbit IgG (H+L) 












Samples were fixed in 4% formalin, embedded in paraffin wax and sectioning 
for histological staining. Sections were incubated overnight at 4 °C with 
TCHP (Abcam, ab-77622; 1:1000). Capillary and arteriole were stained with 
Alexa 488-conjugated isolectin-B4 (Molecular Probes, I2141, 1:100). 
 
ImageJ and CellProfiler analysis  
CellProfiler software was used to build a pipeline (predefined sequence of 
analyses) to quantify the localisation/distribution of fluorescent labelled 
mitochondria. Cells treated with either shRNA scramble (control) or shRNA 
TCHP were grown and stained with DAPI (to identify the nucleus) and 
Phalloidin (to labelled F-actin to identify the cell periphery). Tom20, a protein 
localised to the outer mitochondrial membrane, was labelled with a green 
Alexa Fluor® 488 conjugated antibody. With these organelles and structural 
components labelled CellProfiler was used to aid in quantifying the intensity 
of Tom20 signal on a large number of images/cells. The intensity of the 
Tom20 signal in sequential areas/rings from the nucleus were measured to 
quantify the distribution/localisation of the mitochondria. Analysis performed 
by Mr Gian-Marco Melfi .  
 
Quantification of mitochondrial localization – CellProfiler 
Quantification of mitochondrial localisation within defined areas/distance from 
the nucleus was achieved using CellProfiler. This software allows semi-
automated analysis of batches of images. A pipeline was designed and 








RNA extraction and quantitative real-time analysis 
Total RNA was extracted using miReasy kit (Qiagen). For mRNA analysis, 
cDNA was amplified by quantitative real-time PCR (qPCR) and normalized to 
18S ribosomal RNA. Each reaction was performed in triplicate. Quantification 
was performed by the 2–ΔΔCt method (Schmittgen and Livak 2008). Primers 
are listed in table 4. 
Table 4:  Forward and Reverse primers for each gene assessed by 

















































Cells transfection, transduction and functional assays  
HUVECs were transduced at 20 MOI using MISSION shRNA Controls or 
MISSION shRNA TCHP Lentiviral (SIGMA) particles. Cells were incubated 
with the viral supernatant for 12h. Transduced HUVECs were lysed for RNA 
extraction between 72h and 1week after transduction, as indicated in figure 
legends. Lipofectamine RNAiMAX (Invitrogen) was used to transfect 
HUVECs, with pre-miR-503, pre-miR-control (50nM final concentration), 
according to the manufacturer's instructions. The following functional assays 
were performed: BrdU incorporation assay using Cell Proliferation 
colorimetric assay (Roche); Caspase-activity assay using CaspaseGlo assay 
(Promega); migration assay was performed using wound healing assay as 
oreviously described (Caporali, Meloni et al. 2011). Matrigel assay with 
HUVECs was performed as previously described using BD Matrigel 
Basement Membrane Matrix (BD Biosciences)  
 
 
ATP Colorimetric/Fluorometric Assay 
1 x 106 cells were lysed in 100µl ATP Assay Buffer. Protein were removed 
by cell lysate using 10 kDa Spin Column (Cat. # 1997 Biovision). 50µl of 




prepared for the colorimetric assay, diluting 10µl of the ATP Standard with 90 
µl of dH2O to generate 1 mM ATP standard. 0, 2, 4, 6, 8, 10 µl were added 
into a series of wells and adjusted to 50 µl/well with ATP Assay Buffer to 
generate 0, 2, 4, 6, 8, 10 nmol/well of ATP Standard. To each well was 
added 50µl of Reaction Mix ( ATP Assay Buffer 44µl, ATP Probe 2µl, ATP 
Converter  2 µl ,Developer 2 µl). After an incubation time of  30 min at room 
temperature, protected from light, were measured  the absorbance (OD 570 
nm) or fluorescence (Ex/Em = 535/587 nm) in a microplate reader. The 
signals are stable for over two hrs. Samples concentration was derived 
interpolating the respective OD to the standard curve values. 
 
NAD/NADH Quantitation 
Cellular content was extracted with 400µl of NADH/NAD Extraction Buffer by 
freeze/thaw two cycles (20 min. on dry ice, then 10 min. at room  
temperature), or by homogenization. Samples were centrifuged at 14000 rpm 
for 5 min and transferred in tubes. To detect total NADt (NADH and NAD), 
50µl of extracted samples were transferred into labelled 96 well plates. To 
detect NADH, NAD needed to be decomposed before the reaction. To 
decompose NAD, extracted samples were heated to 60°C for 30 min in a 
water bath or a heating block. Under this condition, all NAD has been 
decomposed, while NADH was still intact. Cooled 50µl of NAD decomposed 
samples were transferred into labelled 96 well plate. 10pmol/µl standard 
NADH was generated by dilution and 0, 2, 4, 6, 8, 10 µl of the diluted NADH 
standard were added to a labelled 96 well plate in duplicate to generate 0, 
20, 40, 60, 80, 100 pmol/well standard in a final volume of 50 µl with 
NADH/NAD extraction buffer. 100 µl of Reaction Mix (NAD Cycling Buffer 
98µl ,NAD Cycling Enzyme Mix 2µl) was added to each well of NADH 
Standard and samples. After an incubation of 5min at RT to convert NAD to 
NADH, 10 µl NADH developer was added to each well and leaved from1 to 4 




concentration of NADH was derived interpolating the respective OD to the 
standard curve values.  
 
Luciferase assays 
For 3’UTR stability assay, HEK 293 cells were transfected with pMIR-
REPORTTM Luciferase and pMIR-REPORTTM Renilla constructs carrying 
TCHP 3’UTR and miR-503 or scrambled oligonucleotide sequence (control). 
using Lipofectmin 2000™ In Vitro DNA Transfection Reagent 
(LifeTechnology) Luciferase constructs. Cells were cultured for 48h and 
assayed with the Dual-Luciferase Reporter Assay System (Promega).  
Animal experiments 
Mouse experiments are reported in accordance with Animal Research Report 
of In Vivo Experiments (ARRIVE) guidelines. Experiments were performed in 
accordance with the Animal (Scientific Procedures) Act (UK), 1986 prepared 
by the Institute of Laboratory Animal Resources and under the auspices of 
UK Home Office Project and Personal License.  CD-1 mice were made 
diabetic using streptozotocin (STZ) (Sigma) (Emanueli, Salis et al. 2002) or 
left normoglycemic after STZ buffer administration alone. STZ was delivered 
i.p. for 5 consecutive days (40mg/Kg in citrate buffer per each day). Fourteen 
days after the first STZ injection, glycaemia at fast and glycosuria were 
measured and only those mice with glycaemia above 200 mg/dL and overt 
glycosuria entered the protocol. Absence of hyperglycemia and glycosuria in 
buffer-injected non-diabetic mice was also verified. Animal experiments have 
been performed by Dr Marco Meloni.  
 
Isolation of endothelial cells from mouse limb muscles  
Adductor muscles at 3 mounts in diabetic and non-diabetic mice were rinsed 
and digested with collagenase II (Worthington) plus DNase I (Sigma) using 
gentleMACS™ Dissociator, following the manufacture’s protocol. Next, ECs 




reported in (Larsson, Fredlund Fuchs et al. 2009).  Experiment performed by 
Dr Andrea Caporali. 
 
Statistical analysis 
Comparisons between different conditions were assessed using 2-tailed 
Student’s t test. If the normality test failed, the Mann-Whitney test was 
performed. Continuous data are expressed as mean ± SEM of three 
independent experiments, each performed in triplicate or quintuplicate. P 
value <0.05 was considered statistically significant. Analyses were performed 













Does TCHP regulate EC 






Blood vessel formation by angiogenesis is a complex multistep process that 
requires control and coordination of ECs as well as the pericytes and other 
intra- and extra-vascular supporting cells.   
In stable vessels, ECs typically form a monolayer of quiescent cells that line 
the luminal surface of vascular tubes. In response to pro-angiogenic stimuli, 
ECs loosen their cell–cell contacts, activate proteases that degrade the 
surrounding basement membrane and acquire extensively invasive and 
motile behaviour to initiate new blood vessel sprouting, followed by further 
vascular morphogenesis and maturation (Potente, Gerhardt et al. 2011). This 
disrupted balance of angiogenesis contributes to the pathogenesis of 
numerous disease states including tumour growth and metastasis (Carmeliet 
and Jain 2011). While it is desirable to block the growth of new blood vessels 
under these circumstances, the controlled stimulation of angiogenesis is 
beneficial in ischemic conditions, characterised by impaired local blood 
supply. Considering the potential clinical benefits of therapeutically 
manipulating blood vessel growth and blood flow, the mechanisms regulating 
the angiogenic process have formed a major focus for vascular research over 
the last two decades. 
Disrupted integrity of ECs plays a significant role in the genesis of vascular 
complications due to diabetes, such as delayed wound healing, ischemia and 
accelerated atherosclerosis (Nishikawa, Edelstein et al. 2000, Sheetz and 
King 2002). Early during diabetes, intracellular hyperglycaemia causes EC 
dysfunction and structural changes in large and small arteries, with tissue 
hypo-perfusion and hypoxia. Death of ECs by apoptosis leads to a 
microvascular rarefaction, which favours the formation of peripheral vascular 
diseases (Brownlee 2001). The migration of ECs is crucial for their normal 
integrity and for the process of vessel healing. Different mechanisms have 
been proposed to explain this process, including regulation of endothelial 
NOS (eNOS) (Hamuro, Polan et al. 2002) and increased reactive oxygen 
species (Masotti, Miller et al.) production (Lamers, Almeida et al. 2011). 




generation of vessels by angiogenesis, thereby worsening the recovery from 
an ischemic insult (Martin, Komada et al. 2003). 
There is increasing interest in developing diabetes-targeted therapies, which 
would be more effective than currently available treatments. Thus, the 
discovery and characterization of novel genes and regulatory pathways in 
diabetes-induced vascular complication is of vital scientific interest.		
Recently, our work demonstrated that microRNA-503 (miR-503) has a 
prominent role in diabetes-induced impairment of post-ischaemic reparative 
neovascularisation (Caporali, Meloni et al. 2015) (Caporali, Meloni et al. 
2011). Recovery from ischaemic events is delayed in diabetic patients with 
critical limb ischaemia, due to impairment of reparative angiogenesis, and 
their plasma miR-503 levels are highly elevated. In addition, type-1 diabetes 
increases miR-503 in ECs of mouse ischaemic limb muscles (Caporali, 
Meloni et al. 2011, Caporali, Meloni et al. 2015).  Among the targets of miR-
503 that I identified, I decided to further characterize Trichoplein (TCHP) for 
two main reasons: It is a strong and consistent target of mir503 and its role in 
vascular biology is completely unknown.   
TCHP (alias MITOSTATIN) is a cytosolic ubiquitously expressed 62 kDa 
protein recently identified like keratin-binding protein. Interestingly TCHP was 
shown to relocate during the epithelial differentiation from cytoplasmic 
localization to the cell-cell border, closely associated with desmoplakin 
(Nishizawa, Izawa et al. 2005, Ibi, Zou et al. 2011). 
The highest levels of TCHP RNA expression were detected in the heart, 
skeletal muscle, kidney, liver, and testis (Vecchione, Fassan et al. 2009). The 
TCHP mature transcript consists of a 3.2 Kb mRNA while a larger 5.5 Kb 
transcript was observed in the heart and skeletal muscle, and a smaller of 
1.24 Kb is usually detected in the heart (Vecchione, Fassan et al. 2009). 
TCHP binds the centrosomal proteins Odf2 and Ninein, regulating Ninein 
recruitment to the centrosome, and is, thus, indispensable to the microtubule-
anchoring activity of Ninein at the centrosome (Ibi, Zou et al. 2011). It is 
noteworthy that Ninein appears to have a cytoplasmic distribution in pericyte 




(Matsumoto, Schiller et al. 2008). Migrating ECs have a highly polarized 
structure, with the appearance of membrane ruffles at the leading edge and 
asymmetrical localization of signalling molecules and the cytoskeleton 
(Lamalice, Le Boeuf et al. 2007). There is a growing body of evidence that 
the coordinated action of microtubules and actin filaments is necessary for 
the cell polarization and migration (Li and Gundersen 2008). Thus, the above 
evidence supports an important role for TCHP in regulating EC migration and 
angiogenesis. 
Both Mir-503 and TCHP were shown to have an opposite effect on the cell 
cycle progression. In fact, mir-503 negatively regulates G1 to S phase 
progression (Caporali, Meloni et al. 2011). In contrast TCHP can promote the 
progression through the cell cycle, counteracting primary cilium formation 
through Aurora A kinase activation (Inaba, Goto et al. 2016). Defects in cell 
cycle progression or cilium re-adsorption are associated with cellular 
senescence. Premature senescence of ECs is recognized to play a key role 
in the pathogenesis of diabetic vascular complications (Palmer, Tchkonia et 
al. 2015). When ECs acquire a senescent phenotype, their homeostatic 
functions become impaired as indicated by a decrease in production of nitric 
oxide and an increase in expression of adhesion molecules such as ICAM-1 
(Foreman and Tang 2003). These alternations lead to endothelial 
dysfunction, vascular inflammation, and impaired angiogenesis and vascular 
repair. Specifically, hyperglycaemia promotes senescence of ECs through 
persistent cell cycle arrest in the G1 phase, increasing senescence-
associated β-galactosidase (SA-β-gal) activity and decreasing telomerase 
function. Moreover, senescent cells acquire the Senescence-Associated 
Secretory Phenotype (SASP), which is characterized by the activation of a 
pro-inflammatory transcriptional program (Acosta, Banito et al. 2013, Childs, 
Durik et al. 2015). According to a recent hypothesis, the build-up of cells 
expressing the SASP may promote the development of both diabetes and its 





The identification of TCHP as target of miR-503 led us to examine the 
relationship between these two genes and whether if the miR-503 related 
phenotype described in ECs before is partially due to TCHP downregulation.  
The work herein will attempt to provide more clarity on the role of TCHP in 





3.1.2 Hypothesis  
Since TCHP expression might be negatively regulated by Mir-503 it would be 
interesting to determine whether TCHP loss may partially recapitulate the 
detrimental effects of Mir-503 up-regulation on EC function and whether they 
are modulated by the same stimuli.  
Moreover, considering that TCHP is responsible for proper anchoring of 
microtubules to the centrioles and for Aurora A kinase activation, it seems 
likely that TCHP may play a role at least during ECs migration and 
proliferation; the work described in this chapter addressed the hypothesis 
that:  
 
“TCHP expression is regulated by mir-503 and TCHP loss has an impact on 
EC function.”  
 
3.1.3 Aims 
In this Chapter, I aim to: 
1. Analyze TCHP localization, and regulation by mir-503 and stimuli 
triggering its expression in ECs 
2. Discover whether TCHP inhibition impacts on EC function 
3. Discover whether TCHP inhibition promotes premature 





3.2 Materials and Methods 
Cells	and	cell	culture	
Human Umbilical Vein ECs (HUVECs) and Human Micro Vascular ECs 
(HMVECs) (both from Lonza) were grown in EGM-2 (EBM-2 medium 
supplemented with growth factors and normal 5mM D-Glucose, NG) and 2% 
Foetal Bovine Serum (FBS) (Lonza). To mimic diabetes and ischemia in vitro, 
the ECs were maintained in EBM-2 (growth factor free medium) with 2% FBS 
and 25 mM D-glucose (high glucose, HG). L-Glucose was used as an 
osmotic control (Cont) at the concentration of 25 mM. HUVECs were used 
between P2 and P6 passage. 
 
RNA	extraction	and	quantitative	real-time	analysis	
Total RNA was extracted using miReasy kit (Qiagen). For mRNA analysis, 
cDNA was amplified by quantitative real-time PCR (qPCR) and normalized to 
18S ribosomal RNA. Each reaction was performed in triplicate. Quantification 
was performed by the 2–ΔΔCt method (Schmittgen and Livak 2008). Primers 
are from Sigma (KiCqStartTM Primers). 
 
Cells	transfection,	transduction	and	functional	assays		
HUVECs were transduced at 20 MOI using MISSION shRNA Controls or 
MISSION shRNA TCHP Lentiviral (SIGMA) particles. Cells were incubated 
with the viral supernatant for 12h. Transduced HUVECs were lysed for RNA 
extraction between 72h and 1week after transduction, as indicated in 
Figureure legends. Lipofectamine RNAiMAX (Invitrogen) was used to 
transfect HUVECs, with pre-miR-503, pre-miR-control (50nM final 
concentration), according to the manufacturer's instructions. The following 
functional assays were performed: BrdU incorporation assay using Cell 
Proliferation colorimetric assay (Roche); Caspase-activity assay using 
CaspaseGlo assay (Promega); Matrigel assay with HUVECs was performed 







Impedance based scratch assays and barrier functions experiments 
Infected cells were seeded on ECIS cultureware (8W1E array) and allowed to 
reach confluence. Then a wound in the cellular monolayer was generated in 
by applying a 3-mA, voltage pulse for 20 s, and recovery of the layer was 
monitored by measuring Resistance at 4000 Hz. The assessment of ECs 
barrier functions was performed with Electric Cell-substrate Impedance 
Sensing (ECIS) Zq instrument (Applied Biophysics). Briefly this instrument 
applies a small alternating current and records the impedance, and thus the 
resistance, of the cellular layer. VEGFA was used at 20nM concentration to 
open the endothelial monolayer. 
 
Luciferase assays 
For 3’UTR stability assay, HEK 293 cells were transfected with pMIR-
REPORTTM Luciferase and pMIR-REPORTTM Renilla constructs carrying 
TCHP 3’UTR and miR-503 or scrambled oligonucleotide sequence (control). 
using Lipofectmin 2000™ In Vitro DNA Transfection Reagent 
(LifeTechnology) Luciferase constructs. Cells were cultured for 48h and 
assayed with the Dual-Luciferase Reporter Assay System (Promega).  
 
Western-Blot analyses 
Cells were rinsed once with ice-cold PBS and lysed with Chaps lysis buffer 
(0.3% Chaps, 10 mM b-glycerol phosphate, 10 mM pyrophosphate, 40 mM 
HEPES [pH 7.4], 2.5 mM MgCl2 and one tablet of EDTA-free protease 
inhibitor [Roche] per 25 ml) and 1% Triton X-100. Where specified in the 
Figureures, Chaps lysis buffer was supplemented with 12.5 mM EDTA. 
Western blot was performed as previously described (Caporali, Meloni et al. 
2011). The following antibodies have been used: TCHP (Abcam); mTOR and 









Mouse experiments are reported in accordance with Animal Research 
Report of In Vivo Experiments (ARRIVE) guidelines. Experiments were 
performed in accordance with the Animal (Scientific Procedures) Act (UK), 
1986 prepared by the Institute of Laboratory Animal Resources and under 
the auspices of UK Home Office Project and Personal License.  CD-1 mice 
were made diabetic using streptozotocin (STZ) (Sigma) (Emanueli, Salis et 
al. 2002) or left normoglycemic after STZ buffer administration alone. STZ 
was delivered i.p. for 5 consecutive days (40mg/Kg in citrate buffer per each 
day). Fourteen days after the first STZ injection, glycaemia at fast and 
glycosuria were measured and only those mice with glycaemia above 200 
mg/dL and overt glycosuria entered the protocol. Absence of hyperglycemia 
and glycosuria in buffer-injected non-diabetic mice was also verified. 
 
Isolation of ECs from mouse limb muscles  
Adductor muscles at 3 mounts in diabetic and non-diabetic mice were rinsed 
and digested with collagenase II (Worthington) plus DNase I (Sigma) using 
gentleMACS™ Dissociator, following the manufacture’s protocol. Next, ECs 
were immunomagnetic sorted using a CD31antibody  (Miltenyi Biotech) as 
reported in (Larsson, Fredlund Fuchs et al. 2009).  
 
Immunofluorescence  
80,000 HUVECs cells were plated on fibronectin-coated glass coverslips in 
24-well tissue culture plates. Twenty-four hours later, the slides were rinsed 
with PBS once and fixed for 15 min with 4% paraformaldehyde in PBS at 
room temperature. The slides were rinsed twice with PBS and cells were 
permeabilized with 0.05% Triton X-100 in PBS for 5 min. After rinsing twice 
with PBS, the slides were incubated with primary antibody in 3% BSA O.N. in 
a cold room, rinsed four times with PBS, and incubated with secondary 
antibodies diluted 1:1000 in 3% BSA for 45 min at room temperature in the 









Senescence of ECs was measured using the Cellular Senescence Assay kit 
from Cell Biolabs, Inc. (Cat: CBA-230). The protocol was performed 
according to the manufacturer’s guide. Briefly, TCHP KD and control ECs 
were plated in a 6 well plate.  Upon confluency, cells were initially fixed and 
later incubated with SA-β-gal working solution for 16 hours in a non-
humidified CO2 free incubator at 37°C. 
 
Immunohistochemistry 
Samples were fixed in 4% formalin, embedded in paraffin wax and 
sectioning for histological staining. Sections were incubated overnight at 4 
°C with TCHP (Abcam, ab-77622; 1:1000). Capillary and arteriole were 




Comparisons between different conditions were assessed using 2-tailed 
Student’s t test. If the normality test failed, the Mann-Whitney test was 
performed. Continuous data are expressed as mean ± SEM of three 
independent experiments, each performed in triplicate or quintuplicate. P 
value <0.05 was considered statistically significant. Analyses were performed 












3.3.1 TCHP localization in endothelia cells and vessels.  
Iassessed TCHP expression and localization by immunofluorescence in 
HUVECs.  THCP localized prevalently in the cytoplasm and showed 
extensive overlap with the mitotraker stained mitochondria. However, 
Inoticed that in some cells TCHP displayed a diffuse cytoplasm distribution 
with no obvious localization, suggesting a dynamic regulation of TCHP 
(Figure 3.1A). Moreover, Iexamined the presence and localization of TCHP 
in vessels (Figure 3.1B). Double immunohistochemistry for TCHP and 
Isolectin-B4 (marker of ECs) in mouse limb muscle showed a strong signal 
for TCHP in correspondence of ECs in muscle-associated microvasculature 






Figure 3.1: Localization of TCHP in Ecs and endothelium 
A, Fluorescent microscope images show Mitotraker stained mitochondria and 
TCHP immunostaining in HUVEC cells. Upper panel represents an example 
of TCHP co-localizing with mitochondria, whereas lower panel is an example 
of TCHP distribution in the cytoplasm. Scale bar, 25 µm. B, Localization of 




3.3.2 TCHP is target of miR-503 
It was tested if the micro-503 may have TCHP among one of its targets. 
HUVECs were transfected with pre-miR503 and a scrambled oligonucleotide 
RNA as a control and harvested 72h later for western blot analysis. 
Interestingly TCHP protein level is reduced in HUVECs overexpressing mir-
503 (Figure 3.2A). Next, the 3’ untraslated region (3’UTR) of TCHP mRNA 
was confirmed to be a mir-503 target, by using an in vitro luciferase report 
assay (Figure 3.2B). HEK293T cells ectopically expressing a pMIR-Report 
plasmid carrying the TCHP 3’UTR downstream a luciferase reporter gene 
coupled with the constitutive housekeeping Renilla reporter gene, were 
transfected with either premiR-503 or a scrambled oligonucleotide sequence. 
Subsequently, the relative fluorescence was calculated using Dual-Glo® 
Luciferase Assay System. 
 
Figure 3.2: TCHP is target of miR-503 
A, TCHP protein level in HUVEC transfected with control or miR-503 mimics 
oligonucleotides. B, Luciferase activity calculated in 293HEK cells co-
transfected with Luciferase carrying 3’UTR TCHP and control RNA or miR-
503 mimics oligonuncleotides. Data are means ± SEM, n =  3; *p < 0.05 vs 









3.3.3 TCHP regulation in vitro  
Since micro-RNA 503 (mir-503) is known to be specifically up-regulated in 
HG/LGF condition (Caporali, Meloni et al. 2011), I investigated how TCHP is 
modulated in response to several stimuli. HUVECs and human microvascular 
ECs (HMVECs) (Figure 3.3A-3.3D, respectively) were cultured in condition 
of high glucose (HG, 25mM D-glucose) or low growth factors (LGF) or a 
combination of the two. The HG/LGF condition is intended to mimic 
advanced diabetes, when hyperglycemia is accompanied by cell starvation 
(Caporali, Meloni et al. 2011). The cells were harvested at 24h after 
treatment and TCHP expression was determined by Western Blot and qPCR; 
an additional time point of 5 days treatment was added for the high glucose 
condition. TCHP expression was slightly decreased after 24h in high glucose 
condition compared to the control (25mM non-metabolized stereoisomer L-
glucose was used as an osmotic control) but sharply dropped down when 
cells were co-treated with HG and LGF. Yet HG alone was sufficient to 
trigger a clear TCHP down-regulation after 5 days (Figure 3.3A and 3.3C). 
TCHP mRNA levels followed the same trend of the protein level as shown in 
Figure 3.3B and 3.3D. Moreover, the expression of TCHP in hypoxic 
condition was also analyzed. TCHP protein levels dropped in HUVECs at 24h 
and more consistently at 48h of hypoxia (Figure 3.3E), while mRNA levels of 







Figure 3.3: TCHP regulation in vitro  
A and C, Protein expression of TCHP in HUVEC and Human Microvascular 
Endothelial Cells (HMVEC) cells under normal condition (Wang, Cano et al.), 
high glucose, low growth factor (LGF), HG/LGF for 24h or cultured in HG for 
5 days. E, TCHP protein level in HUVECs under normoxia (21%O2) or 
hypoxia (1%) for 24h. B, D and F, TCHP mRNA expression of the conditions 








3.3.4 TCHP regulation in vivo 
I have examined TCHP expression in a streptozotocin-induced type-1 
diabetes (12 weeks) (Caporali, Pani et al. 2008, Caporali, Meloni et al. 2011) 
and I found reduced level of TCHP expression in diabetic limb muscles 
(Figure 3.4A) as well as in CD31 sorted ECs from diabetic muscle compared 
to non-diabetic one (Figure 3.4B). Moreover, I found that TCHP expression 
is also reduced in ECs sorted from limb muscle of db/db mice (model of type-
2 diabetes) compared to the control mice (Figure 3.4C), whereas TCHP 












Figure 3.4: TCHP regulation in vivo 
A, TCHP protein level in Limb Muscles of non-diabetic or type I diabetic mice. 
B, TCHP mRNA expression in CD31pos cells sorted from non-diabetic or 
diabetic limb muscles (type-1). C, TCHP mRNA expression in CD31pos cells 
sorted from non-diabetic or diabetic limb muscles (type-2). D, TCHP mRNA 
expression in CD31pos cells sorted from aorta of non-diabetic or diabetic mice 






3.3.5 TCHP knockdown affects EC morphology  
To investigate the involvement of TCHP in the regulation of endothelial cell 
cellular physiology, Iknocked down TCHP in HUVECs. The down regulation 
of TCHP was obtained using a lentivirus based delivery of a short hairpin 
RNA targeting TCHP mRNA.  Virus over-expressing a scrambled RNA 
sequence was used as control.  
HUVEC were infected with shTCHP or control and subsequently TCHP 
expression was assessed at 3 and 7 days after transduction using 
quantitative real time PCR (qRT-PCR) (Figure 3.5A). The protein level of 
TCHP was markedly decreased at 7 days as showed by Western blot 
(Figure 3.5B). Notably, TCHP knock down cells (elsewhere referred as 
TCHP KD) undergo to a remarkable phenotypic alteration even noticeable by 
light microscopy. Specifically, they manifested an enlarged flattered round 
shaped morphology with extensive lamellipodia formation and increased 







Figure 3.5: Characterization of TCHP knockdown endothelial cells 
A, TCHP protein level in HUVEC transduced with control or shTCHP 
lentivirus one week after infection. B, Relative mRNA level of TCHP in 
HUVEC transduced with control or shTHP lentivirus after one week from 
infection. C, Bright field images of shTCHP KD or control HUVECs. Scale 
bar, 50 mm. Data B are means ± SEM, n = 3; **p < 0.001 vs control 















3.3.6 Lack of TCHP impairs EC angiogenesis, migration and barrier 
function in vitro 
To examine the impact of TCHP down-regulation on endothelial function, it 
was performed an in vitro Matrigel tubule formation assay. TCHP down 
regulation severely affects the tubule forming capacity of HUVECs, mainly 
reducing the total length of tubule-like structures (Figure 3.6A and 3.6B). 
Coherently, it was observed that reduced level of TCHP also affects HUVECs 
migration properties as measured by wound healing assay  (Figure 3.6C). 
Finally, the barrier function of TCHP KD cells was measured by the analysis 
of impedance. Cell were cultured as monolayer on specific array of the ECIS 
machine and treated with VEGFA at the concentration of 20ng/ml. Through 
the real-time analysis of the impedance, it was possible to detect the change 
in permeability of the EC monolayer. TCHP KD treated with VEGFA showed 










Figure 3.6: Knockdown of TCHP inhibits in vitro angiogenesis, 
migration and endothelial cell barrier function 
A, Endothelial network formation on Matrigel was quantified at 24 h from cell 
seeding and analyzed by quantification of the total length of tubule-like 
structures. B, Representative microphotographs from Matrigel assay. Original 
magnification 10X; scale bar: 100 mm. C, Wound healing assay. D, Barrier 
function analysis in TCHP knockdown cells treated with VEGF (20ng/ml). 
Data are expressed as difference in cell resistance. Data (A, C and D) are 









3.3.7 TCHP KD affects microtubule density and actin localization 
Next, it was examined by immunofluorescence the microtubule cytoskeleton, 
being itself, a fundamental component of the cell migrating machinery. In 
accordance to previous findings demonstrating TCHP participation in 
microtubules binding at the centrosome of epithelial cells (Sarkar, Korolchuk 
et al. 2011), TCHP KD cells presented a decreased density in the 
microtubule network at the microtubule-organizing center (MTOC) and the 
absence of the centrosomal anchored microtubule aster (Figure 3.7A). 
Moreover, actin filaments (stained by phalloidin) were localized in the 
periphery of the cells in TCHP KD cells (Figure 3.7B) leaving fewer actin 













Figure 3.7:  Analysis of microtubule and actin localization in TCHP 
knockdown cells.  
A, Immunofluorescence images of b-tubulin (green) and B, actin (phalloidin 
staining) in control and TCHP KD cells. Nuclei are stained in Dapi (blue). 
Scale bar, 25 µm 
In A: magnification showing the centrosomes inside of a 10 µm2 yellow 










3.3.8 TCHP is required for cell cycle progression  
Analysis of 5-bromo-2'-deoxyuridine (BrdU) incorporation assay showed that 
TCHP downregulation negatively affected cell cycle progression, showing a 
decrease in the number of cells undergoing S phase progression (Figure 
3.8A). Furthermore, analysis of the cell cycle progression by Propidium 
Iodide (Bonora, Wieckowski et al.) staining showed a significant 
accumulation of cells in the phase G2/M of the cell cycle (Figure 3.8B). 
 
 
Figure 3.8: TCHP knockdown impairs cell cycle 
A, Proliferation of Control and TCHP KD HUVECs was measured by BrdU 
incorporation assay. The Absorbance between 370 and 490 nm is shown for 
both cell populations. B, Flow cytometric analysis of cell cycle using PI 
staining. Chart shows percentage of the cell in different phases of cell cycle. 
Data are means ± SEM; n=3; *p < 0.05 versus control, (Student’s t test). C, 




3.3.9 TCHP knockdown sensitizes ECs to cell death in response to 
different cell death inducing stimuli 
To further unravel the phenotype behind TCHP knock down, was tested the 
apoptotic response to different stimuli using Annexin-V/ 7AAD double 
staining. TCHP KD cells displayed significantly higher number of both 
Annexin-V and 7AAD positive cells compared to the control population 
(Figure 3.9A). This difference was further increased when cells were 
exposed 16h to Homocystein (Figure 3.9B). Homocystein is known to induce 
ROS production (Topal, Brunet et al. 2004) and consequently ER stress 
response (Elanchezhian, Palsamy et al. 2012). In agreement, overnight 
treatment of 2 µM Thapsigargin or 5µg/ml Tunicamycin, two known drugs 
inducing ER stress (Oakes and Papa 2015), increased cell death respect to 
control  but  at a slightly lower level than the treatment with Homocystein 
(Figure 3.9C-D). Notably, Homocysteine, Thapsigargin and Tunicamycin 
were reported to induce not only ER stress but for some extend also 
autophagy (Yorimitsu, Nair et al. 2006, Qin, Wang et al. 2010, Vacek, Vacek 
et al. 2012). This consideration leads us to investigate cell death in response 
to Rapamycin a well-known mTOR inhibitor and inducer of autophagy (Kim 
and Guan 2015).  Interestingly, after 16h treatment with 10µM Rapamycin, it 
was observed a sharp increase in cell death in TCHP KD cells. The 
difference in the percentage of death cells was higher than with any other 






Figure 3.9: TCHP knockdown triggers apoptosis in response to cell 
death stimuli 
A Flow cytometry analysis of Annexin V and 7AAD co-stained cells of control 
cells A, or after 16h of treatment with 5µM Homocystein B, 2µM Thapsigargin 
C, 5µg/ml Tunicamycin D or 10µM Rapamycin E. Graphs show the 
percentage of cells for different drug administration conditions and for both 












3.3.10 Gene expression regulation by knockdown of TCHP 
To further dissect the TCHP KD cell phenotype, different subsets of genes 
were screened by qPCR. Performing two-time point, one at 72h and the other 
at 7 days post transduction gave us the possibility to analyze the early and 
late effects driven by TCHP down regulation. At the beginning were selected 
some of the key angiogenic driving genes, underling fundamental process as 
survival, proliferation and differentiation of ECs. However, no significant 
change in gene expression  was detected (Figure 3.10A). Since it has been 
shown that Thapsigargin and Tunicamic increase ER stress, among others 
was introduced a group of gene up-regulated during ER stress condition; yet 
without substantial significant differences in comparison with control cells, 
apart GRP94 gene (Figure 3.10B). Only when a broad spectrum of negative 
cell cycle regulators was tested was possible to undercover a substantial 
increase of CDKN2A (p12) at 3 days and of CDKN2B (p16) at 1 week after 
transduction, thus possibly explaining the marked decrease of proliferation in 
TCHP KD cells (Figure 3.10C). Moreover, it was also assessed a subgroup 
of genes linked with senescent induced inflammatory processes (Davalos, 
Coppe et al. 2010). Interestingly IL6, IL8, MCP1 and TGFβ2 were 
differentially up-regulated after TCHP downregulation (Figure 3.10D).	These 
considerations prompted us to investigate whether TCHP KD cells might 






Figure 3.10: Gene expression regulation in TCHP knockdown cells 
Relative mRNA levels of TCHP and panel of  A, angiogenic genes; B, 
endoplasmic reticulum (ER) stress genes; C, cell cycle regulator gene; or D, 
inflammatory and senescent genes. Graphs represent transcripts measured 
at 72 h and 7 days post TCHP shRNA transduction. n = 3; Data are means ± 











3.3.11 Analysis of the senescence associated phenotype after TCHP 
downregulation 
Control and TCHP KD cells were assessed for Senescence-associated beta-
galactosidase (SA-β-gal) (Figure 3.11A) and p16 (Figure 3.11B), two well-
characterized senescence markers (McHugh and Gil 2018), using X-gal 
staining on fixed cells and WB, respectively. Interestingly KD cells exhibited 
strong β-Gal activity and a sharp increase of p16 protein level at 7 days post-
infection. Moreover, in TCHP KD cells mTOR was phosphorylated (S2448), 
showing the possible involvement of mTOR pathway in the senescence 
process (Figure 3.11B). Another well-defined hallmark of senescence is the 
senescence-associated secretory phenotype (SASP) whose principal 
components are pro-inflammatory cytokines and chemokines (McHugh and 
Gil 2018). Finally, the expression and release of IL8 and IL6 were 
investigated using ELISA and the results showed that TCHP down-regulation 









Figure 3.11: TCHP knockdown induces a senescence-like phenotype	 
A β-Galactosidase activity as reveal by the chromogenic β-Gal substrate X-
Gal in control and TCHP KD cells. B Western Blot assessing the CDK 
inhibitor p16, mTOR, p-mTOR (S2448) in control and KD cells. Analysis of C 
IL8  and IL6 in control and TCHP KD cells determined by ELISA detection kit. 
All the experiments were performed 7 days after viral transduction. Data are 












Our findings reveal for the first time a new mechanism through which TCHP 
preserve EC homeostasis by regulating an important biological process such 
as senescence.  
I shed light on the regulation of TCHP providing evidence for stimuli that 
negatively affect TCHP expression in vitro and in vivo. I demonstrated that 
lack of TCHP alters ECs functions sensitize cells to apoptosis, is associated 
with an increase of senescence associated proinflammatory cytokines.  
 
3.4.1 TCHP localization and regulation 
It has been previously reported that endogenous or expressed TCHP shows 
a punctuate pattern, partly overlapping with mitochondria (Nishizawa, Izawa 
et al. 2005, Vecchione, Fassan et al. 2009). Using a commercial antibody, 
THCP localization is prevalently in the cytoplasm and showed a strong 
overlap with the mitotraker stained mitochondria.  As TCHP lacks a canonical 
mitochondrial targeting sequence or a clear transmembrane domain for 
insertion into the mitochondrial membrane (Vecchione, Fassan et al. 2009), I 
can assume that TCHP doesn’t bind directly mitochondria but it can shift from 
mitochondrial localization to cytoplasm, thus suggesting a dynamic regulation 
in the cells. This kind of regulation could be due to a different repositioning of 
TCHP during different cell cycle stages or under the effect of cellular stimuli 
or stressor. Moreover, THCP localization in different subcellular compartment 
may mirror different functional role played by the same protein. 
TCHP expression in normal human tissues was previously examined using 
two multiple normal-tissue northern blots. All tissues examined (brain, heart, 
skeletal muscle, colon, thymus, spleen, kidney, liver, small intestine, 
placenta, lung, peripheral blood leukocyte, prostate, testis and ovary) 
demonstrated the presence of the 3.2 kb TCHP transcript, albeit at different 
levels. The highest RNA expression was detected in heart, skeletal muscle, 
kidney, liver and testis. A larger 5.5 kb transcript was observed in heart and 
skeletal muscle. A smaller RNA transcript of 1.24 kb was also detected in 




localization of TCHP in the vessels of limb muscles, showing a strong 
correlation between TCHP antibody and Isolectin-B4 (marker for ECs) and 
diffuse staining for TCHP in the myocytes.  
Recently, Caporali lab demonstrated that microRNA-503 (miR-503) has a 
prominent role in diabetes-induced impairment of post-ischaemic reparative 
neovascularisation (Caporali, Meloni et al. 2011, Caporali, Meloni et al. 
2015).   Recovery from ischaemic events is delayed in diabetic patients with 
critical limb ischaemia, due to impairment of reparative angiogenesis, and 
their plasma miR-503 levels are highly elevated. In addition, type-1 diabetes 
increases miR-503 in ECs of mouse ischaemic limb muscles (Caporali, 
Meloni et al. 2011, Caporali, Meloni et al. 2015).  Using different approaches 
I have identified TCHP as target of miR-503.  
Overexpression of miR-503 decreased TCHP protein level in a TCHP 3’UTR 
dependent manner, showing that TCHP is a bona fide target of miR-503. 
Moreover, I have demonstrated that TCHP expression is decrease in ECs by 
HG and LGF conditions and during hypoxia. Moreover, TCHP expression is 
down-regulated in the muscles and ECs from a type I diabetic mouse model. 
Again, our data defined a direct down-regulation of TCHP expression 
orchestrated by miR-503 and showed also an inverse correlation between 
TCHP and conditions known to increase miR-503 expression.  
 
3.4.2 TCHP knockdown impairs EC functions 
The function of TCHP in ECs is still unknown, although its cellular 
localization, expression and function in other cell lines suggest its role in 
regulation of migration, proliferation and angiogenesis. In this Chapter, I have 
provided evidence for impaired endothelial capacity to form tubule-like 
structure in vitro, decrease migration and proliferation as well as appearance 
of abnormal microtubule structure arising from TCHP reduction.  
Silencing TCHP in ECs using lentiviral vector impairs tubulogenesis 
(assessed by in vitro Matrigel assay). To determine whether the observed 
inhibitory effect of TCHP silencing on EC migration and proliferation may be 




morphology of tubulin networks in HUVECs by immunofluorescence staining 
for α-tubulin. In the control, cytoplasmic tubulin filaments showed normal 
appearance, radiating from a central point to the cell periphery. Silencing of 
TCHP in HUVECs, however, produced marked changes in the tubulin 
cytoskeleton organization showing a marked loss of microtubules.  
The profound effects of TCHP depletion on microtubules suggests that 
downregulation of TCHP could compromise EC migration and barrier function 
of ECs. To address this, I treated ECs with shRNA to TCHP and I used ECIS 
machine. The ECIS machine allows the measurement of EC behaviour by 
measuring the complex impedance spectrum of adherent cells growing on 
gold electrodes (Szulcek, Bogaard et al. 2014). Analysis of migration showed 
a significant decreased in percentage of gap closure in TCHP KD cells. In the 
barrier function assay, confluent TCHP KD cells and control cells were 
treated with high concentration of VEGFA (20ng/ml) in order to observe the 
opening of adherent and tight junction (AJ and TJ respectively). VEGFA is a 
potent and powerful permeability inducing cytokine and has profound effect 
on adherent and tight junction (AJ and TJ respectively) acting on multiple 
pathways and at different points of each signal transduction cascade (Weis 
and Cheresh 2005, Claesson-Welsh 2015). TCHP KD cells were subjected to 
an increased VEGF-induced permeability respect to the control. Hyper-
permeability is characteristic of compromised endothelial function in different 
advanced cardiovascular diseases (Weis and Cheresh 2005) and the result 
in TCHP KD cells  seems to suggest a similar dysfunction. VEGFA stimulates 
actin cytoskeleton remodelling at the cell-cell membrane contact site in a 
RAP1 and ROCK-RHO dependent pathway (Rho, Ando et al. 2017), 
therefore is possible that TCHP deficiency may interfere with those events 
since TCHP KD results in defective MTOC and altered actin organization and 
distribution. A second important event occurring at the AJ after VEGFA 
stimulation is the phosphorylation mediated internalization and rerouting of 
VE-Cadherin to the recycling endosomes (RE) (Fukuhara and Mochizuki 




exacerbate the hyper-permeability seen in TCHP KD because of the 
alteration caused to the RE, better described in the next chapter. 
Finally, since TCHP has been previously associated with the regulation of 
cell cycle (Vecchione, Fassan et al. 2009), I have analysed BrdU 
incorporation and PI staining in cells lacking TCHP and controls. BrdU 
incorporation mark the number of cells in S-phase of cell cycle and PI 
staining determined if there is any delay/accumulation in the different phases 
of cell cycle. TCHP KD cells showed a decrease of BrdU incorporation and 
consequently an accumulation on G2/M. This results are in apparent conflict 
with those shown by others in cancer cells (Vecchione and Fassan 
2009),where the absence of TCHP stimulates the progression of the cell 
cycle whereas TCHP overexpression block it. However it is not surprising 
that cancer cells behave in a complete different way than primary cells 
having them lost sensitivity to tumour suppressing pathways and resistance 
to oncogene driving signals. Moreover the abovementioned studies used 
cancer cells adapted to survive to high degree of aneuploidy  and genotoxic 
stress, on the other hands HUVEC like many others primary cells are more 
sensitive to ploidy alteration and DNA damage response.(Bautista-Nino, 
Portilla-Fernandez et al. 2016)  
 
3.4.3 TCHP knockdown sensitizes ECs to apoptotic death  
The partial mitochondrial localization would also explain its potential 
involvement in apoptosis. Mitochondria are central organelles in the 
regulation of apoptosis, mainly by amplifying death signals by the release of 
cytochrome c and other protein cofactors from the inter-membrane space to 
the cytosol, where they activate effector caspases (Tait and Green 2013). 
The mechanisms by which increased expression of TCHP facilitates 
apoptosis remain to be resolved, but it is conceivable that this occurs through 
a mechanism dependent on mitochondria and ER tethering and the 
subsequent calcium efflux from ER to the mitochondria (Cerqua et al. 2010). 
As mentioned previously, the mechanisms through which hyperglycemia 




mitochondrial dysfunction, otherwise known as activation of the mitochondrial 
apoptotic pathway (Duchen 2004). To address if TCHP silencing could affect 
apoptosis in ECs, I tested whether TCHP influences apoptotic responses to 
cell death stimuli. For this purpose, HUVECs were infected with shRNA for 
TCHP or control vector and treated with Homocysteine, Thapsigargin, 
Tunicamycin or Rapamycin. ECs lacking TCHP display increase sensitivity to 
cell death by stimuli triggering an autophagic response and ER stress, 
showing that these two pathways could be involved in the observed 
phenotype. Rapamycin, a well-known mTOR inhibitor, was the most effective 
apoptosis inducer among the treatments. This might reflect a stronger 
reliance for the KD cells on mTOR dependent survival signals, other than a 
defective modulation of the autophagy response. It would be interesting a 
more in depth analysis in order to dissect the between normal apoptosis and 
other kind of programmed induced cell death, like autophagy or ER-induced 
cell death.  
In the end seems that both the gain and loss of function of TCHP might affect 
cells’ viability, although for different reason; while the former increases the 
sensitivity to Ca2+ induced apoptosis, the latter probably affects the capacity 
of the cells to resist to stressful conditions, such as autophagy, ER stress or 
loss of survival signals (mTOR inhibition), resulting in increased cell death. 
 
3.4.4 TCHP knockdown induces premature senescence phenotype  
Based on the data collected on the characterization of TCHP KD cells, I was 
prompted to investigate whether lack of TCHP can influences expression of 
key genes involved in angiogenesis, inflammations, ER stress and cell 
cycles.  
Accordingly, to the presence of defective cell cycle progression, cells with 
decreased levels of TCHP showed a senescent-like phenotype characterized 
by elevate levels of p16 and p12 and transcription and secretion of senescent 
associated pro-inflammatory cytokines, such as IL-6 and IL-8. No significant 





The senescent phenotype was further confirmed by staining for β-
Galactosidase activity and western blot for p16 and mTOR phosphorylation.  
 
3.5 Conclusion  
In conclusion, I have for the first time functionally characterized TCHP in 
ECs.  I have further provided the first evidence that loss of TCHP protein 
expression may play a role in angiogenesis. Our findings support the 
hypothesis that TCHP is critical for EC function. Furthermore, I demonstrate, 
for the first time, that TCHP is implicated in the control of cell growth, 
apoptosis and that lack of TCHP protein induces a premature senescent-like 
phenotype in ECs after 7 days of culture. 
There two key points that I will be investigated further in the next Chapters of 
this Thesis; first the increase of number of vacuoles observed at TEM, the 
strong response to Rapamycin stimulation and the involvement of mTOR 
pathway encouraged us to investigate the role of autophagy in TCHP KD 
cells. Second, the partial localization of TCHP with the mitochondria brought 
us to test the mitochondrial metabolism in TCHP cells and the possible 





















Autophagy is a complex intracellular process that delivers cytoplasmic 
constituents for degradation into lysosomes. Three main types of autophagy 
have been described: (i) microautophagy (Mizushima and Komatsu 2011), 
comprising direct engulfment of cytoplasmic material by lysosomes via 
inward invaginations of the lysosomal membrane, (ii) macroautophagy (Feng, 
He et al. 2014), characterised by the formation of double-membrane 
sequestering compartments termed autophagosomes that fuse with 
lysosomes for delivery of cytoplasmic cargo, and (iii) chaperone-mediated 
autophagy (Klionsky, Abdalla et al. 2012), defined by the association of a 
chaperone complex with a lysosomal-associated membrane protein type 2A 
to degrade cytosolic proteins with a specific targeting motif. Autophagy 
occurs at basal levels in most tissues to allow constitutive turnover of 
cytosolic components but is stimulated by environmental stress-related 
signals (e.g. nutrient deprivation and oxidative injury) to recycle nutrients and 
to generate energy for maintenance of cell viability in adverse conditions 
(Klionsky, Abdalla et al. 2012). In addition to cellular stress, basal autophagy 
can be intensified by specific drugs, indicating that the autophagic machinery 
is a potential therapeutic target for diverse diseases. Indeed, given that 
autophagy is involved in the prevention of different human pathological 
conditions, including heart and liver disease, cancer, neurodegeneration, as 
well as infectious and metabolic disorders, the development of highly specific 
autophagy modulators has become a major clinical priority. 
Basal autophagy also mediates proper cardiovascular function. A variety of 
cardiovascular risk factors cause defective autophagy due to accumulation of 
unfolded proteins within the cells. This induces high levels of metabolic stress 
and impairs functionality of ECs, reducing levels of NO (Bravo-San Pedro, 
Kroemer et al. 2017). Recent studies suggest that autophagy plays a 
protective role for other aspects of endothelial function. For example, 
autophagy has been shown to regulate the release of von Willibrand factor 
from ECs and angiogenic activity as reflected by endothelial sprouting, 




pharmacological modulation of autophagy by blocking mTOR function has 
shown beneficial effects on plaque phenotype. Specifically, local stent-based 
delivery of rapamycin (known as sirolimus for clinical use) showed 
antirestenotic activity and improved vascular healing (Garg, Bourantas et al. 
2013). Therefore, pharmacotherapy with compounds to re-establish 
physiological levels of autophagy and restore EC function in the vasculature 
is an emerging concept for cardiovascular disease, even though a direct 
univocal link between autophagy reactivation and therapeutic benefits is still 
to confirm (Galluzzi, Bravo-San Pedro et al. 2017). Interestingly, the potential 
cardiovascular effect of certain nutraceuticals and common supplements has 
also been linked to an upregulation of endothelial autophagy (Galluzzi, 
Bravo-San Pedro et al. 2017, Bonora, Wieckowski et al. 2018).  
The parameter that is most appealing is that rates of autophagy are coupled 
to rates of vascular aging. Clearly, age is the major risk factor for 
cardiovascular disease and autophagy is increasingly being implicated as a 
modulator of longevity (Gewirtz 2013). Indeed, global gain of function 
approaches demonstrate that autophagy induction can extend murine life 
span (Pyo, Yoo et al. 2013). Analysis of ECs from old versus young mice, as 
well as analysis of ECs from old versus young patients, reveals that older 
ECs have lower levels of BECN1 and higher levels of SQSTM1/p62 
(LaRocca, Henson et al. 2012). Since SQSTM1/p62 is largely cleared 
through autophagy, these results are at least consistent with the notion that 
the aging vasculature has reduced autophagic flux. The notion that this might 
be more than a correlation is supported by pharmacological interventions that 
attempt to increase autophagy. The addition of trehalose (LaRocca, Henson 
et al. 2012) or spermidine (LaRocca, Gioscia-Ryan et al. 2013), two agents 
that stimulate autophagy, appears to reverse aspects of arterial aging. 
Interesting results in terms of SASP suppression have been obtained with the 
mTOR inhibitor rapamycin (Laberge, Sun et al. 2015), which has long been 
known to extend lifespan and health span in mice (Laberge, Sun et al. 2015). 










4.1.2 Hypothesis  
Given the activation of the mTOR pathway and the premature senescent 
phenotype in TCHP KD cells, observed in Chapter 3 and the causal link 
between them and autophagy, I have been interested in analyzing the 
possible involvement of TCHP in regulating the autophagic flux in ECs.  
 
4.1.3 Aims 
The work described here aims to address the hypothesis that:  
“Lack of TCHP impairs autophagic flux in ECs” 
 
In this Chapter, I aim to: 
1. Analyze the autophagic flux in TCHP KD cells 
2. Determine and characterize the role of TCHP in ECs from patients 
with pre-cardiovascular disease  
 
First, the TCHP KD cells will be assessed in order to check critical autophagy 
proteins and determine the autophagic flux in basal and in autophagy 
induced condition. Second, the role of TCHP in ECs from patients with pre-
cardiovascular disease will be explored, matching the expression of TCHP 





4.2 Materials and Methods 
 
Cells and cell culture 
Human Umbilical Vein ECs (HUVECs) were grown in EGM-2 and 2% Foetal 
Bovine Serum (FBS) (Lonza). HUVECs were used between P2 and P6 
passage. 
 
RNA extraction and quantitative real-time analysis 
Total RNA was extracted using miReasy kit (Qiagen). For mRNA analysis, 
cDNA was amplified by quantitative real-time PCR (qPCR) and normalized to 
18S ribosomal RNA. Each reaction was performed in triplicate. Quantification 
was performed by the 2–ΔΔCt method (Schmittgen and Livak 2008). Primers 
are from Sigma (KiCqStartTM Primers). 
 
Cells transduction  
HUVECs were transduced at 20 MOI using MISSION shRNA Controls or 
MISSION shRNA TCHP Lentiviral (SIGMA) particles. Cells were incubated 
with the viral supernatant for 12h. Double reporter retrovirus was developed 
using pBABE-puromCherry-EGFP-LC3B (Plasmid #22418) from Addgene.)	
Western-Blot analyses 
Total protein extracts were obtained resuspending and vortexing cell pellets 
in small volumes of RIPA buffer containing 1 mM sodium orthovanadate and 
Complete Protease Inhibitor Cocktail (Roche Applied Science) and quantified 
with BCA assay. Equal amounts of proteins were loaded onto SDS-
Polyacrilamide gels and transferred to PVDF membrane. The membranes 
were then blocked with 5% non-fat milk in TBST 0,1% and immunoblotted 
overnight at 4°C with different primary antibodies. 
 
Immunofluorescence  
80,000 HUVECs cells were plated on fibronectin-coated glass coverslips in 




with PBS once and fixed for 15 min with 4% paraformaldehyde in PBS at 
room temperature. The slides were rinsed twice with PBS and cells were 
permeabilized with 0.05% Triton X-100 in PBS for 5 min. After rinsing twice 
with PBS, the slides were incubated with primary antibody in 3% BSA O.N. in 
a cold room, rinsed four times with PBS, and incubated with secondary 
antibodies diluted 1:1000 in 3% BSA for 45 min at room temperature in the 
dark and washed four time with PBS. Slides were mounted on glass 
coverslips using Vectashield (Vector Laboratories) and imaged on a 
Fluorescent Microscope. 
 
ECIS migration  
Migration assay was performed using ECIS machine using 8W1LE. 60,000 
cells are grown on the arrays on top of opposing, circular gold electrodes. A 
constant small alternating current is applied between the electrodes and the 
potential across is measured. The insulating properties of the cell membrane 
create a resistance towards the electrical current flow resulting in an 
increased electrical potential between the electrodes. The basis for the 
measurement of the electrical impedance of cells is Ohm's law, a basic 
electro-technical principle, which describes the relation between resistance 
(R), current (I) and voltage (U) in an electrical circuit at a given time (t). The 
gap in the monolayer is performed increasing the voltage on the electrodes. 
Speed is determined as the time the cells re-establish the monolayer.  
 
Aggregates staining  
Aggregates of ECs was measured using the PROTEOSTAT kit from Enzo 
(ENZ-51035-0025). The protocol was performed according to the 
manufacturer’s guide. 
 
Endothelial cells from patients 
The study was performed with the approval of the South-East Scotland 
Research Ethics Committee, in accordance with the Declaration of Helsinki 




premature coronary artery disease and a family history of premature 
coronary artery disease (n = 8) were identified from the outpatient 
department, Royal Infirmary of Edinburgh, Scotland, UK. A control group of 
healthy age- and sex-matched subjects (n = 8) with no evidence of 
significant coronary artery disease following computed tomography coronary 
angiography (CTCA) was recruited from the Clinical Research Imaging 
Centre, Royal Infirmary of Edinburgh. Subjects attended the Clinical 
Research Facility at the Royal Infirmary of Edinburgh for vascular 
assessment and tissue sampling. Vessel wall endothelial cells were isolated 
by wire biopsy for in vitro expansion. 
 
Statistical analysis 
Comparisons between different conditions were assessed using 2-tailed 
Student’s t test. If the normality test failed, the Mann-Whitney test was 
performed. Continuous data are expressed as mean ± SEM of three 
independent experiments. P value <0.05 was considered statistically 






4.3.1 TCHP KD affects autophagy homeostasis 
Transmission Electron Microscope (TEM) revealed a significant increase in 
the number of autophagic vesicles when TCHP is down-regulated in 
HUVECs. Autophagosome were identified as double membrane enclosed 
vesicles while autolysosome as single membrane vacuoles containing 
partially degraded cytoplasmic content (Figure 4.1 A). Immunocytochemistry 
staining revealed an increased number of LC3 and Sequestosome1 
(SQSTM1) positive puncta (Figure 4.2 A). As the other ATG8 family 
members, LC3b undergoes two subsequent post translational modifications, 
cleavage of the C-terminus exposing Gly120 (LC3b I) and conjugation to the 
phosphatidylethanolamine’ s head group (LC3b II), enabling to its decoration 
of autophagyc vacuoles (Mercer, Gubas et al. 2018).  Western blot analysis 
showed an increased level of the lipidated form of LC3b (LC3b II) and an 
increase of SQSTM1 protein levels in TCHP KD cells compared to control 
(Figure 4.2 C). SQSTM1 is an ubiquitin binding protein and an ATG8 binding 
protein. SQSTM1 acts as an autophagosome cargo targeting protein and 
organelles for autophagic degradation. Since cargo receptors are degraded 
by autophagy, increased SQSTM1 stability might indicate a decreased 
autophagic flux (Klionsky, Codogno et al. 2010). Moreover, a time course 
was performed to follow up the accumulation of LC3 and SQSTM1 during the 
time and the samples analyzed by Western blot (Figure 4.3 A).  Interestingly, 
it was possible to notice the accumulation of an additional band cross-
reacting with SQSTM1 antibody and with a higher electrophoretic mobility 
than SQSTM1 at the early time point of 4 days. Even if the nature of this 
second SQSTM1 band was not investigated it was reported a second 
SQSTM1 isoform lacking the first 84 amino acids at the N-terminal with 
comparable electrophoretic mobility(Wang, Cano et al. 2014). Alternatively it 
might have been a cleavage of the full length SQSTM1 by means of Caspase 
6 or 8 (Norman, Cohen et al. 2010). 
To confirm these data, was used as a complementary strategy the tandem 




autophagosomes are labeled with a yellow signal (mRFP-GFP-LC3), and 
their maturation into autolysosomes is attested by a red signal as a result of 
the quenching of GFP fluorescence in lysosomes. As shown in Figure 4.3 B, 
RFP fluorescence was lower in TCHP KD cells compared with control, 
attesting to a decrease in autolysosome formation and a slower autophagic 
flux in cell lacking TCHP. 
 
Figure 4.1: Analysis of autophagic features in TCHP KD endothelial 
cells 
Representative pictures from Transmission Electron Microscopy analysis. 
Red stars are indicating autophagic vacuoles. Chart bars showed the number 
of autophagic vacuoles in TCHP KD and Control cells from 30 cells. Data are 






Figure 4.2: Analysis of LC3 and SQSTM1 accumulation 
A, Immunofluorescent staining for LC3b and SQSTM1. Scale bar=25µm; B, 
LC3b and SQSTM1 puncta per cell were counted using ICTN plugin from 
ImageJ from >80 cells for each condition; C, Western Blot showing LC3b and 
SQSTM1 protein levels in transduced samples at 6 days. Data are means ± 







Figure 4.3: Analysis of autophagic flux  
A, Western Blot showing time course of LC3b and SQSTM1 protein levels in 
transduced samples.  B, Quantification of HUVECs infected with the tandem 
mRFP-GFP-LC3 lentivirus and infected with shRNA TCHP and Control virus. 
Yellow bars represent autophagosomes, and red bars represent 
autolysosomes. Images are representative of three independent experiments 
in which more than 60 cells were observed. Autophagosomes are labeled 
with a yellow signal, whereas autolysosomes are labelled with a red signal. 








4.3.2 Regulation of autophagic flux in TCHP KD cells 
To analyze the regulation of the autophagic flux in TCHP KD cells, were 
performed a set of experiments using an inhibitor of autophagic flux such as 
Bafilomycin and activators of autophagy such as basal medium or HBSS. 
The ionophore Bafilomycin was in fact used to stop the flux at its late stage 
because blocking the lysosome acidification abolishes the digestive power of 
the lysosomes and at the same time prevents the fusion between 
autophagosome and lysosome. As shown in Figure 4.4 A, A time course 
treatment of TCHP KD cells with Bafilomycin further increased the level of 
SQSTM1, showing that the autophagic flux is not completely compromised. 
In fact if the flux was completely impaired already, adding bafilomycine to 
stop the lysosome function would not have had any effect on the total amount 
of SQSTM1.  
To further understand if the partial block of autophagic degradation was 
reversible, control and TCHP KD cells were starved in naked medium 
(EBM2) and the SQSTM1 protein abundance was compared with cells 
growing in full medium (EGM2). SQSTM1 decreased after 24 h of starvation 
and completely disappear at 48 h in TCHP KD samples, showing that the 
autophagic block possibly affects basal autophagy and not starvation induced 
autophagy (Figure 4.4 B). To biochemically analyze the autophagic flux 
dynamically during the time the abundance of LC3b and SQSTM1 were 
analized by Wester Blot in normal and HBSS starved condition with or 
without bafilomycin. During basal condition, after complete autophagic block, 
control cells accumulated more SQSTM1 than TCHP KD cells, while this 
difference was blunted after autophagy induction. Lipidated Lc3b on the other 
hand appeared to accumulate in KD cells at basal condition whereas the 
lipidation rate increase more in control cell than in the KD after autophagy 
stimulation. Finally, the treatment with HBSS re-activated the autophagic flux 
in TCHP KD cells as demonstrated by strong degradation of LC3b II and 
reduction of SQSTM1 (Figure 4.4 C). Indeed, those results were coherent 






Figure 4.4: Control of autophagic flux in TCHP KD endothelial cells 
A, Western blot showing SQSTM1 protein levels in the absence (DMSO) or 
presence of 200 nM BafilomycinA1 (BafA1) for the indicated time points in 
Control and TCHP KD  B, Western blot showing SQSTM1 protein levels 
under normal culture condition (EGM2) or after serum and growth factors 
starvation (EBM2) for the indicated time points in Control and TCHP KD cells. 
C, Western blot of the autophagic flux assessment during 2 hours time point 







4.3.3 TCHP knockdown regulates lysosomal function 
During lysosomal stress or starvation conditions, the transcription factor 
TFEB relocates from the cytoplasm to the nucleus to activate a 
transcriptional program promoting autophagy and lysosomal biogenesis and 
function (Settembre, Di Malta et al. 2011). To test the activation state of 
TFEB in TCHP KD cells were performed immunofluorescence staining using 
an antibody targeting TFEB. In TCHP knockdown cells, but not in the control 
cells TFEB was detected inside the nucleus suggesting a possible activation 
of the transcription factor (Figure 4.5 A). To reinforce this observation, was 
analyzed the expression of a set of genes known to be regulated by TFEB at 
3 and 7 days after knockdown of TCHP (Settembre, Dormitzer et al. 2011). 
Accordingly, most of these genes were up-regulated in TCHP KD cells and 
showed a dynamic regulation between the time points. For example, 
BECLIN1, LC3, CtsB and TFEB genes were highly expressed at 3 days and 
then decreased at 7 days post-infection, whereas ULK1, LAMP1 and LAMP2 
were regulated in the opposite fashion (Figure 4.5 B). Interestingly TFEC 
and TFE3 were also up-regulated: TFEC followed the same trend of TFEB 






Figure 4.5: Activation of autophagic regulators in TCHP KD endothelial 
cells 
A, Staining and quantification for nuclear TFEB in TCHP KD and control cells 
at 7 days. B, Autophagy regulator and effector genes were assessed by 
qPCR in control and TCHP KD HUVECs at 72h and 7 days after TCHP KD; 
Relative expression values to the control are means ± SEM. *p<0.05; 








4.3.4 TCHP knockdown affects endo-lysosomal pathway 
The abnormalities affecting the autophagic flux in TCHP deficient cells may 
suggest a block during terminal stage of autophagy, when autophagosomes 
fuse with late endosome or lysosome (Klionsky, Codogno et al. 2010) 
(Klionsky, Abdalla et al. 2012). These observations prompted us to 
investigate the endosomal and lysosomal compartments as they play a 
fundamental role in the last step of autophagy (Shen and Mizushima 2014). 
Immunostaining analysis using anti CAVEOLIN1 (CAV1), RAB11, RAB5, 
EEA1, RAB7, LAMP1 and LAMP2 antibodies shown a discrete alteration in 
shape and/or distribution for all the endosomal and lysosomal markers tested 
(Figure 4.6 A-F).  For example, CAV1 localization to the rear edge of the 
plasma membrane of a proliferating ECs was lost in TCHP KD cells, and 
instead was relocated to large and scattered membrane domains (Figure 4.6 
A). After TCHP KD the centrosomal fraction of RAB11 appeared to enlarge in 
comparison to control cells (Figure 4.6 B). Both RAB5 and EEA1 vesicles 
showed similar perinuclear enrichment in TCHP KD cells. Moreover, in TCHP 
KD cells both proteins identified considerably enlarged vesicle than in the 
control (Figure 4.6 C-D), perhaps reflecting an increase in the active form 
RAB5-GTP. Control and TCHP KD cells displayed a similar positioning of the 
RAB7 positive structures around the nuclei (Figure 4.6 E). However, in 
TCHP KD cells the signal was more intense, possibly denoting an increase in 
RAB7 recruitment to late endosomes or the presence of other RAB7 positive 
structures like autophagosomes among late endosome vesicles. Finally, 
TCHP KD dramatically affected the cellular positioning of lysosomes as 
showed by LAMP1 and LAMP2 staining, inducing a sharp perinuclear 
clustering of these organelles (Figure 4.6 F). 
To confirm the activation of endo-lysosomal pathway was performed the 
Epidermal Growth Factor (EGF) Receptor (EGFR) degradation assay (Pinilla-
Macua and Sorkin 2015). Endocytosis and subsequent lysosomal mediated 
degradation are the major regulators of EGFR stability after activation by the 
ligand. EGFR degradation kinetic is the prototypic experimental system for 




endocytic trafficking. As shown in Figure 4.7, in TCHP KD cells, was 
detected a significant increase of EGFR degradation when cells were 
stimulated with EGF.  
 
 
Figure 4.6: Analysis of endo-lysosomal pathway  
The endo-lysosomal compartments from Control and TCHP KD cells are 
analyzed by immunofluorescence. A, Endocytic vesicles (CAVEOLIN1) B, 
recycling (RAB11) C-D, early (RAB5, EEA1); E, late (RAB7) endosomes and 
markers were detected by immunostaining. Representative image of 10 







Figure 4.7: TCHP KD increases endo-lysosmal activity 
Representative western blot showing Epidermal Growth Factor Receptor 
(EGFR) expression during pulse chase experiment: after 5 hours of growth 
factor deprivation Control and TCHP KD HUVECs were stimulated with 
20ng/ml EGF for the indicated times. Cells were lysed and processed by 







4.3.5 Accumulation of aggregates in TCHP KD cells 
Protein aggregates called aggregosome are formed in cells with defective 
proteostasis due to inefficient Ubiquitin Proteasome system (UPS) or 
defective autophagy. Aggresomes accumulate in cytoplasmic inclusion 
bodies and are generated in response to aggregates of misfolded proteins 
(Johnston, Ward et al. 1998, Kopito 2000), and depending on the cell types 
and associated misfolded proteins, aggresomes may contain a variety of 
chaperones. Aggresome composition was shown to varying depending on 
the cell types the causes at the base of their origin and the associated 
misfolded proteins for examples most but not all aggresome-associated 
proteins have been shown to be ubiquitinated or they may contain a variety 
of chaperones, proteasome subunits or autophagy related proteins(Wigley, 
Fabunmi et al. 1999, Markossian and Kurganov 2004). Using Proteostat 
dye, which becomes highly fluorescent upon binding to the amyloid-type b-
sheet tertiary structure of protein aggregates (Garcia-Mata, Bebok et al. 
1999) revealed increase number of protein aggregate in KD cells respect to 
control (Figure 4.8 A). The aggresome structure in TCHP KD cells was 
further characterized by immunofluorescence and surprisingly no co-









Figure 4.8: Analysis of aggregosomes 
A, Aggresome staining and quantification of protein aggregates in Control 
and shTCHP cells using PROTEOSTAT® Aggresome Detection kit; Picture is 
a representative image of 8 different fields; n=3. Scale bar 25µm. B, Co-
localization between aggregates (red) and SQSTM1 (green). Scale bar 25µm 
and 10µM for the inset. Data are means ± SEM; **p<0.01 vs. control (n=3); 









4.3.6 Activation of autophagic flux in TCHP KD cells restores migration 
and decrease inflammation 
To confirm that decrease of autophagic flux is involved in the TCHP-
dependent phenotype observed in ECs, I have used Torin-1 to reduce mTOR 
phosphorylation and consequently its negative activity on the autophagic flux.  
Torin-1 is a potent and selective ATP-competitive mTOR inhibitor (Thoreen, 
Kang et al. 2009); therefore Torin 1 treatment of cells leads to the 
dephosphorylation of mTOR downstream targets including p70 S6 kinase, S6 
Ribosomal Protein, and 4E-BP1 (Peterson, Sengupta et al. 2011). Indeed, in 
our experiments, is shown a reduction in mTOR and p70S6K phosphorylation 
and a decrease a p16 in TCHP KD cells treated with Torin-1 for 8 hours 
(Figure 4.9 A).  Interestingly, also SQSTM1 is downregulated by the Torin-1 
treatment (Figure 4.9 B). In agreement with previous studies (Herranz, 
Gallage et al. 2015, Laberge, Sun et al. 2015), I have demonstrated that 
mTOR inhibition also decrease SASP transcription and improved cell 





Figure 4.9: Activation of autophagic flux in TCHP KD cells restores 
migration and decrease inflammation 
A, Western blot for mTOR, p-mTOR, p-S6K and p16 of transduced cells 
treated with DMSO or 100nM Torin1 for 8 hours. n=2. B, Representative 
Western blot showing SQSTM1 protein levels in the absence (DMSO) or 
presence of 100 nM Torin-1 for the indicated times in Control and TCHP KD 
HUVEC cells. C, IL-6, IL-8, IL-1β were assessed by qPCR in control and 
TCHP KD HUVECs either treated with vehicle (DMSO) or 100nM Torin-1. D, 
Migration speed of control and TCHP KD were measured by ECIS Zθ. Data 




4.3.7 ECs from patients with premature coronary artery disease have 




I have then analysed the expression of TCHP, SQSTM1 and SASP genes in the 
ECs from patients with premature coronary artery disease. These ECs have been 
obtained from vessel wall from patients with endothelial dysfunction had significant 
impairments in proliferation, adhesion and migration (Brittan, Hunter et al. 2015). 
Gene expression analysis showed that ECs from patients express low level of 
TCHP and high level of SQSTM1 and SASPs genes in comparison of ECs from 





Figure 4.10: Analysis of TCHP, SQSTM1 and SASP genes in ECs from 
patients with premature coronary artery disease 
Expression assessed by qPCR of A,miR-503, B, TCHP, C, SQSTM1 D, IL-
1β, E IL-8 and F IL-6 in ECs from vessels wall from patients with premature 
coronary artery disease. *p<0.05 vs. Healthy subject. Data are means ± SEM 
(n=8).  
 
4.3.8 Torin-1 restores EC functionality in ECs from patients with 




To confirm that the downregulation of TCHP in ECs from patients contribute 
to the similar phenotype observed in TCHP KD cells, I have treated the cells 
with Torin-1 and analysed SASP gene transcription and migration. As shown 
in Figure 4.11 A-B, Torin-1 treatment for 8 hours reduced cytokines 
transcription and improved the migration of ECs from patients. Moreover, I 
have demonstrated that ECs from patients has an accumulation of 
aggregates compared with ECs from healthy donors. Treatment with Torin-1 
also reduced the accumulation of aggregates within the ECs from patients 







Figure 4.11: Activation of autophagic flux in ECs from patients with 
premature coronaric artery disease restores migration and decrease 
inflammation 
A, The expression of selected genes SQSTM1, IL-6, IL-8 and IL-1B was 
measured by qPCR in ECs from healthy subject and patients either treated 
with vehicle (DMSO) or 100nM Torin1. B, Migration speed from healthy and 
patients ECs either treated with vehicle (DMSO) or 100nM Torin1 were 
measured by ECIS Zθ,. C, Staining and quantification of aggregates in ECs 
from healthy subject and patients either treated with vehicle (DMSO) or 
100nM Torin1. Scale bar 25µm. Data are means ± SEM; *p<0.05; **p<0.01 





4.3.9 Characterization of TCHP knockout mice 
In collaboration with the Wellcome Trust-Sanger Institute, I have obtained a 
set of tissues from Tchp knock out mice and relative wild-type control (age-
matched).  IHC from different tissues were performed using SQSTM1 and 
CD31 to identify vessel. Preliminary analysis of the myocardial tissue from 
TCHP knockout mice at 16 week-of-age exhibited a reduced heart 
vascularization and significant accumulation of SQSTM1/p62 in the 




Figure 4.12 Expression of SQSTM1 in TCHP KO mice 
A, Detection of SQSTM1 in the heart of Wild-type (WT) and TCHP KO (Tchp 






Our findings highlight an unexpected role for TCHP in EC homeostasis by 
regulating cellular proteostasis. I demonstrated that lack of TCHP are found 
in dysfunction EC and are accompanied by the appearance of a senescence-
like phenotype. Here I have shown that TCHP KD in HUVECs impairs basal 
autophagy leading to the accumulation of unresolved autophagosomes, 
SQSTM1 and protein aggregates.  
4.4.1 Regulation of autophagic flux by TCHP 
In order to analyse the autophagy in TCHP KD and to interpret autophagic 
flux in the cells were performed transmission electron microscopy, 
immunocytochemistry, Western blot and the use of LC3 double reporter 
(Klionsky, Abdelmohsen et al. 2016). Altogether, the assays performed 
reported a reduced autophagic flux in TCHP KD cells. Analysis of the LC3 
and SQSTM1 showed that lack of TCHP can influence the accumulation of 
these two proteins in ECs. The results obtained using the LC3 double 
reporter vector reinforce the concept that autophagic flux is reduced in TCHP 
KD cells.  
An interesting follow up of these results would be the identification of the 
specific point where the autophagic flux is delayed. Several experiments will 
be necessary to understand if the reduction of autophagic flux is due to an 
impairment of the autophagosome formation, closure or fusion with 
lysosomes. Interestingly, SQSTM1 did not co-localize with aggregates and 
this might play a role in the impaired degradation of protein aggregates 
through SQSTM1. Analysis of the ubiquitination and association with HDAC6 
may provide a more complete set of information about the nature of these 
aggregates and their formation explaining whether there is any impairment in 
the binding of SQSTM1 or in the labelling tagging the aggregates for the 
destruction route.     
Finally, I have also assessed that the autophagic flux in these conditions is 
not completely blocked but it is reversed by starvation, opening the possibility 








4.4.2 Regulation of endolysosomal pathway 
TCHP KD cells showed an interesting change in the localization and intensity 
of components of endo-lysosomal pathway.  
CAV1 is the principal scaffolding protein of caveolae on the plasma 
membrane with a critical role in endocytosis and in EC polarization and 
directional migration (Beardsley, Fang et al. 2005).  CAV1 was recently 
identified as a negative regulator of autophagy and lysosomal function 
through two different mechanisms: one dependent on the interaction with the 
ATG12-ATG5 autophagic regulatory system and the other by maintaining 
lipid rafts integrity (Chen, Cao et al. 2014, Shi, Tan et al. 2015).  Because the 
role of CAV1 in ECs as transported of eNOS and VEGFR, the loss of CAV1 
positive vesicles on plasma membranes in TCHP KD cells need further 
investigation and  
RAB11 resides in the recycled endosome structure and participates in a 
number of cellular processes comprising primary cilium assembly, 
phagophore formation, autophagosome maturation and fusion with MVB/LE 
or lysosome (Longatti and Tooze 2012).  After TCHP KD the centrosomal 
fraction of RAB11 appeared to enlarge in comparison to control cells.  
RAB5 and EEA1 are early endosomal proteins, although while EEA1 has a 
more close and specific localization, RAB5 can be present in the plasma 
membrane, clathrin-coated vesicles, and early endosome that mediates 
fusion of endocytic vesicles to form early endosomes (Ao, Zou et al. 2014). 
RAB5 after activation by its GEF, Rabex-5, binds EEA1 and other effectors to 
promote endosome fusion.(Mizuno-Yamasaki, Rivera-Molina et al. 2012). 
Rab5 is part of a macromolecular complex containing Beclin1 and Vps34, 
and participates in autophagosome formation (Tanida 2011). Both RAB5 and 
EEA1 vesicles are enlarged and showed similar perinuclear enrichment in 




Rab7 is located on late endosome and promotes microtubule plus-end-
directed transport and fusion of autophagosomes with lysosomes. Rab7 
when in its active GTP-bound form, binds to Rab7-interacting lysosomal 
protein (RILP) regulating the microtubule minus-end-direct transport of late 
endocytic vesicles and phagosomes by recruiting the dynein–dynactin motor 
complex (Lamb, Longatti et al. 2016). TCHP KD cells the signal was more 
intense, possibly denoting an increase in RAB7 recruitment to late 
endosomes or the presence of other RAB7 positive structures like 
autophagosomes among late endosome vesicles. 
LAMP1 and LAMP2 specifically reside on the lysosome membrane. LAMP2 
is a core component of chaperone mediate autophagy, a process that 
involves  chaperon assisted loading of target protein directly in the lysosome 
through a LAMP2 core complex (Cuervo and Wong 2014). TCHP KD cells an 
increase of lysosomal intensity and a change of position of these organelles. 
Coherently to the repositioning of the different intermediates of the 
endosomal pathway the EGFR pulse chase kinetics revealed a faster 
degradation of EGFR in KD than control cells. The endolysosomal pathway 
seems in fact more active in the absence of TCHP and a possible reason for 
that is the attempt of the KD cells to cope with the stall of basal autophagy, 
potentiating parallel sources of nutrient like endocytosis or micro-autophagy, 
both relying on the endolysosomal pathway.  
 
4.4.3 Regulation of TCHP-related phenotype by mTOR inhibitor 
The pharmacological modulation of autophagy by blocking mTOR function 
has shown beneficial effects on several diseases (Galluzzi, Bravo-San Pedro 
et al. 2017).  Since I have determined that mTOR pathway is strongly 
activated in our experimental model, I decide to use Torin-1 in order to 
inhibits mTOR pathway and activate the autophagic flux in the cells.  
The mTOR kinase inhibitor Torin-1 blocks the phosphorylation of all 
mTORC1 substrates more efficiently than rapamycin does, and as a result 
Torin-1 elicits stronger autophagy induction in both mouse and human cell 




transcription was previously reported on seminal studies on senescence and 
mTOR regulation (Herranz, Gallage et al. 2015, Laberge, Sun et al. 2015). 
As expected, 8 hours treatment of Torin-1 reduced SQSTM1 accumulation; 
moreover, Torin-1 strongly reduced accumulation of p16 in TCHP KD cells, 
decreased the transcription of inflammatory cytokine, thus improving EC 
migration.  
Finally, I have further confirmed these results using ECs from the vessel wall 
from healthy subjects and from patients with premature coronary artery 
disease.  These patients with endothelial dysfunction were identified and 
selected by measurement of forearm blood flow using venous occlusion 
plethysmography before and during intra-arterial infusions of endothelial-
dependent and -independent vasodilators (Brittan, Hunter et al. 2015). 
Moreover, the methods for the expansion and maintenance in culture of 
vessel wall endothelial cells from both patients and healthy controls was 
adapted from an endothelial biopsy protocol and allow long-term in culture of 
the cells (Brittan, Hunter et al. 2015). 
The traditional paradigm of vascular repair is based on the proliferation and 
migration of existing mature ECs from the adjacent vasculature (Psaltis and 
Simari 2015). The vessel wall ECs from patients with endothelial dysfunction 
have reduced proliferation, adhesion and migration suggest that local 
mechanisms of vascular repair are impaired in patients who develop 
premature coronary artery disease. Treatment with Torin-1 for 8 hours 
reduced the transcription of inflammatory cytokines, increase proliferation 
and reduced the protein aggregates within the cells. Although Torin1 is able 
to trigger a strong autophagic response its use in clinic results improbable 
because of its non specific action on mTOR1 and mTOR2  and potential 
dangerous side effects. Rapamycin and its derivates (Rapalogs ) may 
represent a better option since maintains mTOR2 active and preserve the 
capacity to activate autophagy. For reason concerning the cytostatic and 
anti inflammatory action exerted by rapamycin, rapalogs eluting stent  are 




effects on smooth muscle cells and immune cells, the cytotoxic effect on 
endothelial cells is still source of preoccupation. At this regard it should be 
noted that the positive effect induced by TORIN1 to TCHP KD  and PCAD 
EC comes from a transient treatment with the drug and thus free from the 
cytotoxic side-effect associated with long exposure. Furthermore it would 
be valuable taking in consideration a different strategy and try to increase 
TCHP expression to improve patients' EC functions. For example a possible 
approach might involve Decorin stimulation to increase TCHP level (Neill,T.et 
al 2014).  
 
4.4.4 Tchp in vivo study  
Immunohistochemistry microscopy was performed on paraffin embedded  
tissue from Tchp KO mice kindly donated by the Wellcome Trust-Sanger 
Institute.  Results from this in vivo study confirmed one of the major finds 
already observed during the in-vitro and ex-vivo study that is the strong 
increased of SQSTM1 after TCHP loss. More importantly IHC on myocardial 
tissue of KO mice showed for the first time the detrimental effect of TCHP 
loss on the vasculature network. Decrease capillary density in Tchp KO in 
partially anticipated by the results coming from in vitro studies, is of 
fundamental importance not only because it is the first example of organ 
dysfunction linked to TCHP deficiency and remarks the critical role of this 
protein in the cardiovascular system, but also it opens other interesting 
perspective like the role the endothelial specific knock-out of Tchp during 
high-fat diet or post-ischaemic angiogenesis after myocardial infarction or 
limb ischemia. 
 
4.4.5 Conclusion  
In this Chapter, I have demonstrated that insufficient levels of TCHP leads to 
inefficient autophagy and this in turn contributes to the development of 




attenuation, not only curbs endothelial migration, but also promotes an 
inflammatory and senescent phenotype. Importantly. Ex-vivo study showed 
that pharmacological activation of autophagy in ECs from patient’s vessel 
wall with premature coronary disease, improved EC migration and reduce 
inflammation. Altogether, these findings underline the role of TCHP in 
endothelial autophagic flux control and suggest autophagy activation by 
Torin-1 as a protective mechanism in TCHP deficient cells, thus showing that 
stimulation of autophagy may be an attractive strategy in the prevention of 











Does TCHP regulate 







Mitochondria have often been described as the energy factories of the cell. In 
numerous cell types, mitochondria produce large amounts of cellular energy 
required by the cell in the form of adenosine triphosphate (ATP). ATP is also 
produced in large quantities in the cytosol via the process of glycolysis. 
However, other major ATP producing metabolic processes are contained 
within the mitochondrial membranes namely, the Krebs cycle and oxidative 
phosphorylation (OXPHOS) via the electron transfer chain (Giedt, Pfeiffer et 
al. 2012). It is important to note that in previous years mitochondria have 
been shown to be highly functionally dynamic organelles with many non-
bioenergetic roles. These roles include the regulation of intracellular Ca2+ 
homeostasis as well as in the production of reactive oxygen species (Masotti, 
Miller et al.) related to oxidative stress (Gutierrez, Ballinger et al. 2006, 
Davidson and Duchen 2007, Murphy 2012). The ability of mitochondria to 
produce ROS has emphasized their importance in influencing cell signalling 
pathways including the importance of ROS in apoptosis inducing pathways 
specifically (Willems, Rossignol et al. 2015). 
It has been shown that ECs produce the majority of their cellular energy via 
glycolysis in the cytosol (Xu and Erzurum 2011) as opposed to in the 
mitochondria. These finding have lead researchers to identify the importance 
of non-biogenetic roles endothelial mitochondria play in the vasculature 
specifically.  
Mitochondria are highly mobile organelle and evidence suggests that their 
spatial localization changes according to the needs of the cell (Murphy 2012). 
Therefore, their non-bioenergetic roles can be modulated by the localization 
of the organelles which has significant implications in the context of the 
mitochondria’s involvement in signalling pathways. 
One of the most important functions of mitochondria within cardiovascular 
cells, particularly ECs, is their ability to produce ROS (Caja and Enriquez 
2017). Excessive production of these species has been linked to 




development and/or the progression of many cardiovascular pathologies. It 
was first thought that ROS were predominantly produced because of 
mitochondrial dysfunction and solely contributed to cell death via their effect 
on apoptosis pathways. More recent work has pointed to the importance of 
ROS as important secondary messengers, regulating several cellular 
signalling pathways present at basal levels. ROS have been shown to be 
produced by the oxidative phosphorylation (OXPHOS) complexes I and III via 
single electron reduction of oxygen (Tang, Luo et al. 2014). This production 
does occur at a basal level but is often increased during mitochondrial 
dysfunction. The reactive oxygen species produced is predominantly 
superoxide and, if produced in sufficiently high quantities, can overwhelm the 
ECs endogenous antioxidant defences leading to an increased oxidative 
stress state (Li, Dietz et al. 1997). Endothelial dysfunction in diabetic patients 
has been linked to increased ROS and reactive nitrogen species (Silvander, 
Kvarnstrom et al.) (Son 2012). ROS can directly modify mitochondrial 
(OXPHOS) proteins and in so doing exacerbate ROS production and its 
potential detrimental effects on the cell at high levels.  
Mitochondrial ROS production has been implicated in hypoxia signalling/gene 
expression regulation in the nucleus. Specifically, the combined effect of the 
localization of mitochondria around the nucleus and increased oxidative 
stress results in the increased concentration of ROS inside the nuclear 
envelope. The co-localization of mitochondria and the nucleus results in a 
smaller total distance necessary for ROS to diffuse into the nucleus. The 
increased intra-nuclear ROS has been shown to stabilize oxygen-sensitive 
pro-hypoxia transcripts (Al-Mehdi, Pastukh et al. 2012). 
Since recent studies indicate that TCHP plays an important role in the 
physiology of mitochondria (Vecchione, Fassan et al. 2009, Cerqua, Anesti et 
al. 2010), in this chapter, I have taken different approaches to analyse the 
effect of lack of TCHP has on mitochondria position and function. This study 
will try to provide for the first time whether TCHP promotes a fission-like 




nuclear membranes. Moreover, analysis of ROS production and 





5.1.2 Hypothesis  
Since TCHP is partially localize with the mitochondria, thus possibly effecting 
ROS production and mitochondria functionality; the work described in this 
Chapter aims to address the hypothesis that:  
“Lack of TCHP impairs mitochondrial function and bioenergetics in ECs” 
 
5.1.3 Aims 
In this Chapter, I aim to: 
1. Analyse the effect of the downregulation of TCHP on the 
localization of mitochondria  
2. Investigate the effects of the lack of TCHP on mitochondrial 





5.2 Materials and Methods 
Cells and cell culture 
Human Umbilical Vein ECs (HUVECs) (Lonza) were grown in EGM-2 (EBM-2 
medium supplemented with growth factors and normal 5mM D-Glucose, NG) 
and 2% Foetal Bovine Serum (FBS) (Lonza). HUVECs were used between 
P2 and P6 passage. 
 
Western blot 
Proteins were transferred to polyvinylidene difluoride (PVDF) blotting 
membrane. Membranes were hybridized with the following antibodies: 
Mitochondrial OXPHOS complexes cocktail (Abcam/MitoProfiler®Total); anti-
PARP1 (Abcam); Anti-Rabbit IgG (whole molecule)–Peroxidase antibody 
produced in goat; Anti-Mouse IgG (whole molecule)–Peroxidase antibody 
produced in sheep. Chemiluminescent detection of proteins of interest was 
achieved using Immobilon™ Western Chemiluminescent HRP Substrate kit 
(Millipore). The Western blots were developed on X-ray film and quantified 
using UN-SCAN-IT gel™ version 6.1.  
 
Native-PAGE of mitochondrial electron chain complexes 
To assess the effect of TCHP KD on the electron transport chain (ETC) also 
referred to as OXPHOS complexes, Native-PAGE was used to separate the 
different complexes while in their native conformation followed by western 
blotting. All products were used according to manufacturer’s instructions. The 
Novex® NativePAGE™ Bis-Tris gel system purchased from Thermo Fisher 
Scientific was used to separate the mitochondrial electron chain complexes. 
Kit included Invitrogen NativePAGE™ 3-12% Bis-Tris Gels. NativePAGE™ 
20X Cathode Buffer Additive. Native-PAGE™ 20X Running Buffer. As well as 






Mitochondrial isolation protocol 
To separate OXPHOS complexes using Native-PAGE, mitochondria were 
isolated from control and TCHP know-down HUVECs. The mitochondrial 
isolation protocol used by (Frezza et al. 2007) to isolate mouse embryonic 
fibroblasts was used as a starting point to develop the protocol in HUVECs. 
Cells were harvested and suspended in ice cold IBc buffer (10 ml of 0.1M 
Tris-MOPS, 1 ml of EGTA/Tris, 20 ml 1M sucrose made to 100 ml in H2O, 
pH = 7.4, Complete™ protease inhibitor added). Cells were then 
homogenised using a Teflon pestle. A number of centrifugation steps 
followed in order to isolate the mitochondria from the homogenate. 
Mitochondria isolates were solubilised as per the manual provided with the 
Native-PAGE system. Digitonin detergent provided in the sample prep kit 
was used at a final concentration of 2.5% v/v which was found to yield the 
best solubilisation results.  
 
Seahorse: Mitochondrial respiration stress test 
The Seahorse XFe24, Extracellular Flux analyser manufactured by Agilent 
Technologies was used to conduct a mitochondrial stress test to quantify key 
parameters of mitochondrial respiration under control and TCHP know-down 
conditions. Control HUVECs and TCHP know-down were plated into 
Seahorse XF24 V7, 24 well microplate plates and grown to 70% confluence 
before analysis at either day three and seven days after infection.  
 
Flow	cytometry	
Both control and TCHP know-down cells were analysed to determine total 
mitochondrial mass and relative levels of mitochondrial ROS. 
MitoTacker®Green FM – Mitochondrial probe (used to determine 
mitochondrial mass) Life Technologies, (100nM). MitoTracker®Red CM-
H2XRos – Mitochondrial ROS probe (used to quantification mitochondrial 








HUVECs cells were plated on fibronectin-coated glass coverslips in 24-well 
tissue culture plates. Twenty-four hours later, the slides were rinsed with PBS 
once and fixed for 15 min with 4% paraformaldehyde in PBS at room 
temperature. The slides were rinsed twice with PBS and cells were 
permeabilized with 0.05% Triton X-100 in PBS for 5 min. After rinsing twice 
with PBS, the slides were incubated with primary antibody in 3% BSA O.N. in 
a cold room, rinsed four times with PBS, and incubated with secondary 
antibodies diluted 1:1000 in 3% BSA for 45 min at room temperature in the 
dark and washed four time with PBS. Slides were mounted on glass 
coverslips using Vectashield (Vector Laboratories) and imaged on a 
Fluorescent Microscope. Antibodies:  Tom20 mouse monoclonal IgG (Santa 
Cruz Biotechnology/(FL10); Phalloidin; Green fluorescent Alexa Fluro® 488 
anti-mouse. A Zeis Axioskop HBO 50 florescence microscope equipped with 
a Photometrics® coolSNAP HQ2 CCD camera and QImaging® CRI 
Micro*Color 2 RGB Liquid Crystal Tunable Filters was used to acquire 
imaging.  
 
ImageJ and CellProfiler analysis  
CellProfiler software was used to build a pipeline (predefined sequence of 
analyses) to quantify the localisation/distribution of fluorescent labelled 
mitochondria. Cells treated with either shRNA scramble (control) or shRNA 
TCHP were grown and stained with DAPI (to identify the nucleus) and 
Phalloidin (to labelled F-actin to identify the cell periphery). Tom20, a protein 
localised to the outer mitochondrial membrane, was labelled with a green 
Alexa Fluor® 488 conjugated antibody. With these organelles and structural 
components labelled CellProfiler was used to aid in quantifying the intensity 




Tom20 signal in sequential areas/rings from the nucleus were measured to 
quantify the distribution/localisation of the mitochondria. Quantification of 
mitochondrial localisation within defined areas/distance from the nucleus was 
achieved using CellProfiler. This software allows semi-automated analysis of 
batches of images.  
 
Statistical analyses 
All statistical analyses were performed using GraphPad Prism v5.01. The 
predominant test used was the students paired t-test, which was used to 
assess the difference between the mean values of paired data sets 





5.3.1 Lack of TCHP does not affect mitochondria localization  
The general rearrangement of endolysosomal vesicle systems identified in 
the previous Chapter persuaded us to further investigate the mitochondrial 
localization. The mitochondria’s localisation with respect to the nucleus was 
assessed by immunoflorescence using The MitoTracker™ Green FM probe 
to label specifically mitochondria, followed by ImageJ and CellProfiler 
analysis (Figure 5.1). The median fluorescent intensity (MFI) is reported as a 
percentage of the total MFI measured in the full area analysed (nucleus/0 – 
16 µm). By expressing the MFI as a percentage of the total an impression of 
the distribution/localisation of all mitochondria analysed per cell is described 
(Figure 5.1 C). The experiments were performed on samples labelled 7 days 
after infection. TCHP KD and control cells seemed to have similar 








Figure 5.1: Analysis of mitochondrial localization in TCHP KD and 
control cells 
Assessing the localisation/distribution of mitochondrial using confocal 
microscopy and CellProfiler image analysis software. TCHP KD and control 
cells were analysed at 7 days after transduction.  A, Cell stained for Tom20 
(green) and Phalloidin/F-actin (red) Scale bar 25µm. B, Final output image 
generated by the CellProfiler pipeline. After nuclei were identified, the cell 
periphery was identified using the red/F-actin (Phalloidin) channel. Each 
nucleus then acted as a seed for subsequent 2 µm rings to be draw radiating 
from its periphery. C, MFI of mitochondria in 2 µm rings from the nucleus 
expressed as a percentage of the total MFI measured in the 0 – 16µm area 
analysed. More than 30 cells from 3 different field per experiment were 








5.3.2 Quantification of total mitochondrial mass and ROS in TCHP KD 
cells 
Mitochondria are highly dynamic organelles that can change their subcellular 
redistribution to redirect ROS signal into the nucleus during hypoxia (Al-
Mehdi, Pastukh et al. 2012). The total mitochondrial mass of HUVECs 
infected with control or shRNA TCHP lentivirus respectively was assessed 
using flow cytometry. The MitoTracker®Green FM probe was used to label 
mitochondria specifically, irrespective of membrane potential. No significant 
effect on mitochondrial mass due to TCHP KD was detected at 3 or 7 days 
post infection using this method (Figure 5.2 A). The MitoTracker™ Red CM-
H2XRos fluorescent mitochondrial ROS probe was used and HUVECs were 
analysed at 3 days and 7 days after infection. A significant increase in 
mitochondrial ROS production was detected at 7 days after infection (Figure 
5.2 B). Finally,  using CellROX™ probe to analyse the level of total ROS in 
the cells, was shown that the total ROS in the cells are not affected in TCHP 






Figure 5.2: Quantification of total mitochondrial mass and ROS 
TCHP KD and control cells were labelled at 3 and 7days after infection. A. 
Quantification of total mitochondrial mass using flow cytometry; graph 
showing total MFI values. B. Mitochondrial ROS were determined by 
MitoTracker™Red CM-H2XRos (emission spectra at wavelength 610 nm). C, 
Total cell ROS analysis were determined by CellROX™ (emission spectra at 










5.3.3 Analysis of mitochondrial function with respect to mitochondrial 
respiration in cell lacking TCHP 
To evaluate the effect of the lack of TCHP on mitochondrial respiration, the 
Seahorse mitochondrial stress tests were performed on control and TCHP 
KD cells. The stress test was performed on cells 7 days after infection and 
results are shown in Figure 5.3 B. The Seahorse XF24 extracellular flux 
analyser provides cellular respiration in steady-state conditions and after the 
addition of specific inhibitors for selected mitochondrial electron transport 
chain complexes. Oxygen consumption rate over time was measured in 
control and TCHP KD cells. Cellular respiration was calculated and dissected 
into mitochondrial and non-mitochondrial respiration using Rotenone and 
Antimycin A inhibitors of complex I and complex III, respectively (Figure 5.4 
A-B). Mitochondrial respiration was further dissected into proton leak as the 
residual oxygen consumption after R/A treatment (Figure 5.4 D) and ATP-
linked respiration (Figure 5.4 E) using the ATP-synthase inhibitor, 
Oligomycin. The portion of spare respiratory capacity was obtained by 
subtracting basal respiration from maximal respiration rates induced by the 
FCCP drug treatment. Interestingly reserve capacity of TCHP KD cells was 






Figure 5.3: Seahorse XF Cell Mito Stress Test analysis of cell lacking 
TCHP 
A. Exemplifying image of Seahorse XF Cell Mito Stress Test response profile 
(Sutendra, Dromparis et al.) and picture (left) describing the respective drugs 
used and which ETC complex/s they inhibit Source image available at 
https://www.agilent.com/en/products/cell-analysis/mitochondrial-respiration-
xf-cell-mito-stress-test.  B, Oxygen Consumption Rate (OCR) over time from 
control and TCHP knockdown cells calculated using a SeaHorse X24 







Figure 5.4:  Analysis of Seahorse experiments parameters  
Oxygen consumption rates (OCR) for cellular respiration A, mitochondrial 
and B, non-mitochondrial; C, reserve capacity, D, proton leak, E, ATP linked 
respiration and, F, mitochondrial reserve capacity were analyzed using 
specific electron transport Chain ETC inhibitors; Data are means ± SEM, 








5.3.4 Analysis of relative abundance of electron transport chain 
complexes in TCHP KD cells 
Decreased mitochondrial spare capacity is often due to a reduced expression 
of one or more components of the Electron Transport Chain (ETC). Native-
PAGE was specifically employed to ensure the complexes were kept in their 
native conformation (intact tertiary and quaternary structures) to better 
visualise potential changes to these complexes under TCHP KD conditions. 
Figure 5.5 is representative of three replicate experiments in which aliquots 
of mitochondria solubilised with 2.5% v/v digitonin were run on a Native-
PAGE gel. The pixel intensities of the Native-western blots were normalised 
using the Red Ponceau of the correspondent SDS-PAGE gels as well as 
being normalised against complexes levels from control cells (Figure 5.5 B).  
Interestingly, ETC complexes revealed an overall trend of increasing levels of 
mitochondrial ETC machinery present under TCHP KD conditions 7 days 
after infection. However, every precaution was taken to insure accurate 
loading of the Native-PAGE wells by means of BCA total protein analysis. A 
second precaution was taken to correct for potential loading error. The SDS-
PAGE gels were loaded with the same amount of total protein per lane, 2 µg, 
as the Native-PAGE gels. These SDS-PAGE gel lanes were used to 





Figure	 1 Figure 5.5: Analysis of mitochondrial ETC/OXPHOS protein 
complexes  
HUVECs were transduced with either shRNA scramble (control) or shRNA 
TCHP lentivirus analyses was perfeormed at 7 days after transduction A. 
Western blot analysis of 5 different  proteins representing the 5 different 
multisub-units complex enzymes constituting the ETC. B, Pixel quantification 
of all complexes detected in western blots. The solid line at 1 across the Y-
axis indicates the normalised control Fold∆. The labelled bars on the graph 
represent the relative abundance of each complex visualised through pixel 










5.3.5 TCHP KD affects energy balance in ECs 
Potentially a deficit in the mitochondrial reserve capacity may be due to 
problems that affect one or more of the components of the ETC or may be 
related to a lack of intermediates fuelling the chain with their electrons 
(Dranka, Hill et al. 2010). In this section it was considered the latter option. I 
assessed the levels of total Nicotinamide adenine dinucleotide NADt (NAD+ 
and NADH) (Figure 5.6 C) at 3 and 7 days after transduction and detected a 
marked fall at 3 days in KD cells and was only partially recovered at the later 
time point (Figure 5.6 A). Since NAD is a cofactor for GAPDH, a decrease in 
its bioavailability might affect the glycolytic process. Three days post-infection 
was observed an initial decrease in ATP in KD cells, followed by a sharp drop 
at 7 days compared to controls (Figure 5.6 B). Moreover, to understand the 
reasons for NAD decline, I separated nuclear and cytoplasmic fractions from 
control and KD cells, which revealed that the most prominent reduction was 
restricted to the cytoplasm (Figure 5.6 ). NAD is consumed by three classes 
of cellular proteins: CD38, Sirtuins and members of the Parp family (Canto, 
Menzies et al. 2015). To further investigate the causes behind the NAD 
decrease I have checked two of the most likely potential consumers of NAD: 
SIRT1 and PARP1. In TCHP KD cells SIRT1 expression as determined by 
qRT-PCR was slightly increased at 3 days but subsequently decreased at 7 
days (Figure 5.7 A). PARP1 levels and activity were examined by WB and 
were strongly decreased in TCHP KD samples at 7 days post-infection 
(Figure 5.7 B-C). Therefore, if our observed effect was not due to NAD 
exhaustion I proposed that it may be a result of a recycling defect, as the 
NAD recycling pathway takes place in the cytoplasm. Consequently, I 
decided to test the expression of Nicotinamide phosphoribosyltransferase 
(NAmPRTase or Nampt), the rate limiting enzyme involved in NAD recycling. 
However, I noticed significantly higher levels of NAMPT in TCHP KD cells 






Figure 5.6: TCHP KD affects energy balance of the cells 
Quantification of A, total NAD+ and B, ATP in Control and TCHP KD using a 
bioluminescent (StayBrite ATP Assay Kit) and a colorimetric (NAD+/NADH 
Quantification Colorimetric Kit) kit respectively; C, Quantification of total NAD 
[NADt (NAD+ and NADH)]. D, Nuclear and E, cytoplasmic quantification of 
both NADH and total NAD [NADt (NAD+ and NADH)] in Control and in TCHP 








Figure 5.7: TCHP KD regulates SIRT1 and PARP1 abundance.  
A Relative SIRT1 mRNA expression in Control and TCHP KD cells; C, 
PARP1 abundance and D, parylated protein products assessed by WB in 
Control and TCHP KD cells; E levels of NAMPT protein revealed by Western 
blot analysis in Control and KD cells. Data are means ± SEM, n=2; *p < 0.05 






5.4 Discussion  
Since TCHP was shown to be associated with the outer mitochondrial 
membrane (Cerqua, Anesti et al. 2010), the main hypothesis of this Chapter 
was to assess what impact, if any, does TCHP KD have on the functionality 
of endothelial mitochondria. I was therefore interested in understanding 
whether lack of TCHP would have any detrimental effects on mitochondrial 
function and localization. 
 
5.4.1 Mitochondria localization and size 
Analysis of mitochondria localization in TCHP KD showed a no significant 
difference compared with control cells, even though the outline trend of 
moving mitochondria towards the nuclei took shape. To confirm the trend the 
number of cells to analyse need to be increased and more accurate 
quantification up to the plasma membrane might be required. Moreover, 
before further molecular testing of the mitochondria could be performed with 
confidence, quantification of total mitochondrial mass under both control and 
TCHP KD conditions were assessed. The results obtained show no change 
in mitochondrial mass in TCHP KD HUVECs at 7 days. 
 
5.4.2 Effect of TCHP KD on ROS production 
Elevated levels mitochondrial ROS are often positively correlated to 
increased cellular stress. Previous work has shown the importance ROS can 
play as secondary messengers influencing gene expression under particular 
stress conditions (Al-Mehdi, Pastukh et al. 2012). Due to the role, ROS has 
been shown to play in cellular stress response and endothelial dysfunction 
(Madamanchi and Runge 2007), I aimed to quantify the mitochondrial ROS 
levels in control vs TCHP KD cells. A significant change in mitochondrial 
ROS was evident under TCHP KD conditions at 7 days after infection. This 
results might be in agreement with the previous chapter results, in fact there 
are evidence that increase ROS are require to induce and expand the 




increased ROs in KD cells might be the cellular response to the decline of 
autophagic flux. In addition ROS elevation may contribute, through NF-KB 
activation, to the pro-inflammatory phenotype seen aster TCHP loss. 
5.4.3 Mitochondria bioenergetics 
To assess TCHP KD effect on the ability of mitochondria to respond to stress 
Seahorse mitochondrial respiration analysis was performed. The Seahorse 
XF Mito Stress Test generated profiles that describe the mitochondria’s 
ability to respond to several stresses. The stresses are induced by the 
sequential additional of compounds that inhibit specific regions of the ETC 
machinery. Inhibiting these complexes over a time course while measuring 
OCR allows numerous aspects of mitochondrial function to be assessed. I 
have demonstrated that TCHP deficiency strongly reduced the mitochondrial 
reserve capacity, a characteristic feature of mitochondrial dysfunction. 
Reserve mitochondrial capacity could be a measure of how much 
mitochondria are able to adapt their energy production in stress situation 
requiring increased energy demand. Noteworthy, reduced reserve capacity is 
often associated with mitochondrial dysfunction in a series of different 
pathological condition (Brand and Nicholls 2011). Moreover the reserve 
capacity may be considered an indirect measurement of the efficiency by 
which mitochondrial complexes work so a reduction in mitochondrial reserve 
capacity might underlie a functional and or structural defect of ETC 
complexes. 
Isolation and separation of the ETC/OXPHOS complexes using Native-PAGE 
was performed to further investigate potential deficit in their abundance or 
structural defect. Quantification of the Western blots showed an increase in 
all mitochondrial complexes under TCHP KD conditions, therefore, a general 
increase in oxidative phosphorylation machinery is present in mitochondria 
seven days in TCHP KD. The complex that was shown to increase most 
under TCHP KD conditions was complex III/CoQH2-cytochrome c reductase. 
This observation was interesting as it has been suggested that increased 
electron leakage from complex III and complex I both contributed to greater 




al. 2010). Increased levels of both these complexes particularly complex III 




5.4.4. Effect of TCHP KD on EC energy balance 
Reduced mitochondrial reserve capacity may alternatively been caused by 
insufficient bioavailability of substrate supplying the TCA cycle or deficiency 
in essential ETC complex enzyme cofactors NADH and FADH. To this regard 
were measured the concentration of ATP and NAD/NADH. Interestingly both 
ATP levels and total NAD (NADt) dropped in TCHP KD cells. Reduced 
glycolysis may have been the cause for less ATP produced, moreover since 
NAD is a cofactor for GAPDH, an essential glycolytic enzyme, the observed 
decline in ATP may be secondary to the fall in NADt bioavailability. The 
reduction in NADt concentration might be caused by an increased 
consumption rate or a delay in the recycle of the intermediate following the 
utilisation by cellular enzymes. Given that PARP1 and SIRT1, two major NAD 
consumers, are indeed down-regulated in our model, It was sensitive to 
hypothesize a possible defect in the NAD recycling chain. To further address 
this point was checked the abundance of NAMPT, the rate liming step 
enzyme for the NAD salvage pathway. Surprisingly were observed increased 
levels of NAMPT possibly suggesting a compensatory reinforcement of the 
NAD salvage pathway, to better cope with decreasing NAD levels. Data of 
this part are very preliminary and need further investigation, for example only 
the main NAMPT over a total of three isoforms was assessed and this may 
lead to incomplete picture of the total NAD salvage capacity of the cell. 
Secondly it would be desirable and more relevant testing the enzymatic 







5.4.5 Conclusion  
In summary, the effect of TCHP KD on mitochondrial functionality was first 
assessed by quantifying total mitochondrial ROS. This experiment showed 
no statistically significant change in mitochondrial ROS levels. Secondly 
mitochondrial mass was quantified using two methods. Using flow cytometry 
and imaging analysis, I have demonstrated no persuasive change in 
mitochondrial mass. Investigation into the ETC complexes revealed an 
overall trend of increasing levels of mitochondrial ETC machinery present 
seven days after TCHP KD. Finally, Seahorse analysis revealed a change in 
the ability of mitochondria to respond to stress in TCHP KD cells. This 

















The vascular endothelium, the functional lining of blood vessels, plays a 
critical role in vascular homeostasis. Whereas normal endothelial function is 
thought to be atheroprotective, endothelial dysfunction is increased in 
atherosclerotic conditions such as coronary heart and peripheral artery 
disease (PAD) and is an independent predictor of future cardiovascular 
events. The most severe form of PAD, critical limb ischaemia (CLI), occurs 
when arterial blood flow is restricted, causing inadequate perfusion of 
capillary beds to sustain tissue viability. About 20% of the UK population 
aged 55-75 years suffer PAD, equating to a prevalence of 850,000 people, of 
whom 5% have symptomatic critical limb ischaemia (CLI) (Aboyans, Ricco et 
al. 2017). Although endovascular interventions and open surgical techniques 
are the main therapeutic options for limb salvage, a significant proportion of 
patients with CLI are not eligible and foot amputation remains the ultimate 
alternative, with an associated yearly mortality rate >25%.  There is an 
increasing interest in identifying novel targets and developing therapy to 
improve endothelial function in the hope to reduce disease progression and 
future cardiovascular risk. There is evidence that endothelial dysfunction in 
patients with PAD can be improved; however, development of additional 
medical therapies for endothelial dysfunction is an area of unmet medical 
need with a currently limited research pipeline. 
The work contained in this thesis was designed to clarify the role of TCHP in 
EC function and its mechanisms. The work utilised a number of experimental 
approaches to provide a complete picture of the role of TCHP in ECs through 
the regulation of autophagy and, hence, reveal whether it is a promising 
target for further investigation. 
 
6.1 TCHP in endothelial cell function 
The TCHP gene is located on chromosome 12q24 that is frequently deleted 
in a variety of malignant neoplasms (Shiseki, Kohno et al. 1996, Schmutte, 
Baffa et al. 1997, Sattler, Rohde et al. 1999, Aubele, Cummings et al. 2000). 




it is deleted or mutated in about 11% of various cancer-derived cell lines and 
solid tumors. Reduced TCHP expression was found in 22% of advanced 
bladder cancers and in 23% of breast carcinomas analysed (Vecchione, 
Fassan et al. 2009, Kim, Kim et al. 2010, Fassan, D'Arca et al. 2011). A 
specific link between TCHP overexpression and the decreased level of the 
heat-shock protein Hsp27 and its cellular phosphorylation status has been 
previously determined (Vecchione, Fassan et al. 2009). Hsp27 shows 
cytoprotective effects, it interferes directly with caspase activation, modulates 
oxidative stress and regulates cytoskeleton scaffolding (Parcellier, Schmitt et 
al. 2003).  
Using a commercial antibody, THCP localization was predominantly in the 
cytoplasm and showed a strong overlap with the MitoTracker-stained 
mitochondria.  As TCHP lacks a canonical mitochondrial targeting sequence 
or a clear transmembrane domain for insertion into the mitochondrial 
membrane (Nishizawa, Izawa et al. 2005, Vecchione, Fassan et al. 2009), I 
can assume that TCHP doesn’t bind directly mitochondria but it can shift from 
a mitochondrial localization to the cytoplasm, thus suggesting dynamic 
regulation in the cell.  The function of TCHP in ECs has not been investigated 
before, although its cellular localization, expression and regulation of Hsp27, 
suggests it has a role in regulation of migration, proliferation and 
angiogenesis.  
Microtubules and the actin cytoskeleton function in cooperation in normal 
endothelium and under conditions of barrier loss and impairment of 
migration. Their coordination is accomplished at several levels by cross-linker 
proteins which join microtubules and actin filaments (Bershadsky, Kozlov et 
al. 2006), as well as by small GTPases of the Rho family which mediate 
dynamics and organization in both the actin network and microtubules 
(Palazzo, Joseph et al. 2001). The cytoskeleton reorganization can change 
the cell shape to provoke intercellular gap formation and provides structural 
basis for a hyperpermeability, the main cause of vascular endothelial 
dysfunction. This phenomenon is common for a number of pathological 




ischemia, diabetes) and can lead to severe, and even fatal, organ 
dysfunction (Bogatcheva and Verin 2008, Kasa, Csortos et al. 2015). 
Chapter 3 reported evidence that reduced TCHP in endothelial cells impaired 
their capacity to form tubule-like structures in vitro, to migrate and proliferate, 
and caused the appearance of abnormal microtubule structure. In controls, 
cytoplasmic tubulin filaments showed normal appearance, radiating from a 
central point to the cell periphery. Silencing of TCHP in HUVECs, however, 
produced marked changes in the tubulin cytoskeleton organization showing a 
complete loss of microtubules, thus regulating EC migration and barrier 
function of ECs. 
One of the most dramatic changes of microtubule organization is found at the 
transition from interphase to mitosis during cell cycle. During mitosis, 
microtubules are much more dynamic and are organized into a dense bipolar 
structure, the spindle, whereas microtubules in interphase are less dynamic 
and are arranged in a radial array (Meunier and Vernos 2012). In agreement 
with the role of microtubules during cell cycle, I observed a reduction in S 
phase and an accumulation in G2/M phase of cell cycle in TCHP KD cells 
compared with control.  
Consistent with defective cell cycle progression, cells with decreased levels 
of TCHP showed a senescent-like phenotype characterized by elevated 
levels of p16 and p12, and transcription and secretion of senescence-
associated pro-inflammatory cytokines, such as IL-6 and IL-8.  The 
senescent phenotype was further confirmed by staining for β-Galactosidase 
activity and western blot for p16 and mTOR phosphorylation.  
Centrosomes are the tiny organelles found in most eukaryotic systems. By 
their ability to anchor, organize and nucleate microtubules, they play a crucial 
role in establishing spindle bipolarity and in ensuring the fidelity of cell 
division. Defects in centrosome structure and function often result in mitotic 
catastrophe, cell cycle arrest, cell death, genomic instability and/or 
aneuploidy, leading to human disorders such as primary microcephaly, 




instability and aneuploidy are also hallmarks of aging and cellular 
senescence (Hernandez-Segura, Nehme et al. 2018).  
Our understanding of the connection between TCHP downregulation and 
senescence remains undeveloped. In this Thesis, I have focused on existing 
evidence suggesting that these two phenomena are indeed related, along 
with the emerging view that TCHP downregulation represents a form of 
cellular stress that is necessary and sufficient to trigger a permanent cell 
cycle arrest and senescence. 
Finally, of interest for this Thesis, a series of recent publications has revealed 
that the biogenesis and trafficking of autophagosomes depend on the 
activities of several cytoskeletal components, including actin assembly 
factors, membrane–cytoskeleton scaffolds, signalling proteins, and 
microtubule- and actin-based motors (Kast and Dominguez 2017). The 
analysis of the phenotype of TCHP KD cells and the strong impact on 
microtubule organization prompted analysis of the involvement of the 
autophagic pathway in TCHP KD cells.   
 
6.2 TCHP as novel regulator of autophagy  
Autophagy is an essential quality control function of the cell. It selectively 
degrades harmful protein aggregates and/or damaged organelles, enabling 
maintenance of cellular homeostasis. Basal autophagy also mediates proper 
cardiovascular function. A variety of cardiovascular risk factors cause 
defective autophagy due to accumulation of unfolded proteins within the 
cells. This induces high levels of metabolic stress and impairs functionality of 
ECs, reducing level of NO (Nussenzweig, Verma et al. 2015). Recent studies 
suggest that autophagy plays a protective role for other aspects of 
endothelial function. For example, autophagy has been shown to regulate 
both the release of von Willibrand factor from ECs, and angiogenic activity 
(as reflected by endothelial sprouting, proliferation, and tube formation; 




In this Thesis, I have shown that TCHP downregulation impairs basal 
autophagy leading to the accumulation of unresolved autophagosomes, 
SQSTM1 and protein aggregates. Although the exact molecular mechanism 
remains not completely known, I have disclosed a widespread alteration of 
autophagic flux; but showing a strong activation of the endolysosomal 
pathway.  
The experiment reported in Chapter 4 provided a clear interpretation of the 
blockage of the autophagic flux.  Accumulation of LC3 and SQSTM1 and the 
use of the LC3 double reporter vector demonstrated that autophagic flux is 
reduced in TCHP KD cells. Experiments are on-going in the lab to 
understand whether the reduction of autophagic flux is due to an impairment 
of the autophagosome formation or closure.  Moreover, I have also assessed 
that the autophagic flux in these conditions is not completely blocked but it is 
reversed by starvation, opening the possibility that TCHP-dependent 
reduction of autophagy could be pharmacologically re-activated.  
Interestingly, I have observed an activation of the endolysosomal pathway in 
TCHP KD cells.  The collection and transport of cellular waste to lysosomes 
requires complex logistics. The cell has developed different routes for 
transporting extracellular and intracellular waste to the lysosome. 
Extracellular material reaches the lysosome mainly through endocytosis. The 
capture of extracellular material and integral membrane proteins occurs 
through specific endocytosis mechanisms according to the nature of the 
cargo. After internalization, the receptors are routed to early endosomes 
(Sorkin and von Zastrow 2009). From the endosomes, the receptors can 
either be recycled back to the plasma membrane to allow for repeated 
receptor activation, or be sorted and targeted for lysosomal degradation, 
resulting in the termination of receptor signalling (Raiborg and Stenmark 
2009). 
Intracellular materials reach the lysosome through the process of autophagy, 
a “self-eating” catabolic pathway that is used by cells to capture their own 
cytoplasmic components destined for degradation and recycling. Three types 




autophagy and macroautophagy. During microautophagy, cytosolic proteins 
are engulfed into the lysosome through the direct invagination of lysosomal 
or endosomal membranes (Sahu, Kaushik et al. 2011). In chaperone-
mediated autophagy, cytosolic proteins are transported into the lysosomal 
lumen through chaperone- and receptor-mediated internalization, which 
requires the unfolding of proteins and their translocation through the LAMP2a 
protein (Cuervo and Dice 1996). Macroautophagy, herein referred to as 
autophagy, relies on the biogenesis of autophagosomes, double membrane-
bound vesicles that sequester cytoplasmic material and then fuse with 
lysosomes (Ravikumar, Sarkar et al. 2010). Thus, the role of all three types 
of autophagy in degradation and recycling processes is strictly dependent on 
lysosomal function. 
 
6.3 Role of TCHP in mitochondrial function and bioenergetics 
TCHP plays an important role in the physiology of mitochondria (Vecchione, 
Fassan et al. 2009, Cerqua, Anesti et al. 2010). TCHP reside on outer OMM 
where they make contact with Mfn2 promoting a fission-like phenotype and a 
redistribution of mitochondria near the nuclear membranes (Vecchione, 
Fassan et al. 2009, Cerqua, Anesti et al. 2010). Moreover, TCHP regulates 
ER–mitochondria tethering via Mfn2 acting as a negative modulator of ER–
mitochondria juxtaposition and conferring resistance to H2O2-induced cell 
death (Cerqua, Anesti et al. 2010). Recently, it has been reported that 
keratins, likely through TCHP-mtf2 interactions, regulate both structural and 
dynamic functions of β-cell mitochondria, which could have implications for 
downstream insulin secretion (Silvander, Kvarnstrom et al. 2017). In line with 
these studies, I have investigated the role of TCHP in EC mitochondria and 
the contribution of TCHP in ROS production and mitochondrial bioenergetics. 
Although our results are still preliminary, TCHP KD cells showed an 
interesting profile.  
First, the lack of TCHP in ECs did not affect the position of mitochondria, 




reported (Cerqua, Anesti et al. 2010). The main difference between my 
results and the previous studies is on the use of a cell line instead of primary 
cells, such as HUVECs. Indeed, HUVECS already have very long 
mitochondria and knock-down of TCHP neither affected their position nor 
promoted a fission-like phenotype. Interestingly, TCHP KD cells showed an 
increase in mitochondrial ROS, showing a possible activation of stress 
signalling within the cells. These results need further investigation because it 
is not clear whether the level of mitochondrial ROS produced by the cells is 
critical to determine the phenotype observed in the ECs. However, these 
results prompted analysis of mitochondrial respiration and function using 
Seahorse technology.  
The ETC is the major site of non-enzymatic superoxide formation within 
mitochondria (Turrens 2003). The ETC is made up of four multi-protein 
complexes (I-IV) embedded in the inner membrane. Complex I and II oxidize 
NADH and FADH2 respectively, transferring the resulting electrons to 
ubiquinol, which carries electrons to Complex III. Complex III shunts the 
electrons across the intermembrane space to cytochrome c, which brings 
electrons to complex IV. Complex IV then uses the electrons to reduce 
oxygen to water. Mitochondrial complexes I, II, and III generate superoxide 
(Murphy, Bers et al. 2009). Complex I and II generate ROS within the 
mitochondrial matrix while complex III generates ROS into either the matrix 
or the intermembrane space (Treberg, Quinlan et al. 2010) . Superoxide 
generated in the intermembrane space can escape into the cytoplasm 
through voltage-dependent anion channels (Han, Antunes et al. 2003). 
Using several small molecules which inhibit the mitochondrial complexes 
during the Seahorse experiment, I have demonstrated that TCHP deficiency 
strongly reduced the mitochondrial reserve capacity, a characteristic feature 
of mitochondrial dysfunction (Brand and Nicholls 2011). 
With this in mind, I have then quantified the amount of mitochondrial 
complexes using Native-Page gel. The analysis showed an increase of 
complex III/CoQH2-cytochrome c reductase in TCHP KD cells. The results 




therefore cell with increased level of complex III should show a reduced level 
of ROS.  
Moreover, mitochondrial complex III is responsible for the production of ATP 
in the cells. Analysis of energy production in the cells showed that ATP levels 
dropped and total NAD amount is reduced at 7 days after TCHP KD.  
The discrepancy of results between the level of mitochondria bioenergetics 
and the total content of ATP and NAD in the TCHP KD cells showed the 
possible involvement of pathway that exclude a direct involvement of 
mitochondria in the control of energy balance of the cells.  Indeed, glycolysis 
is essential as ECs primarily rely on this pathway for ATP production. A 
future line of research will be analysis of the metabolic pathway and glucose 
metabolism in TCHP KD cells. 
 
6.4 Future work 
6.4.1 Identification of TCHP partner proteins and their functions  
In proliferating cells, TCHP serves as a hub not only for appendage-
associated NIN involved in microtubules anchoring at the mother centriole 
(Ibi, Zou et al. 2011) but also for centriole-associated AuroraA implicated in 
the destabilization of cilia (Inaba, Goto et al. 2016). On the other hand, in 
differentiated, non-dividing epithelial cells, TCHP is translocated from 
centrioles to keratin filaments and desmosomes (Nishizawa, Izawa et al. 
2005). Thus, the function and localization of TCHP depend on its partner 
proteins. This observation immediately raises the question of which proteins 
directly interact with TCHP in the ECs. This part of the study will be 
performed in collaboration with University of Edinburgh Proteomic Facility. To 
identify proteins that interact with TCHP, Iwill express an epitope-tagged 
TCHP (FLAG-TCHP) in the cells using a plasmid. After a FLAG-
immunoprecipitation, partner proteins are separated by gel-electrophoresis, 
then subsequently digested in-gel with a protease (typically trypsin) and 
analysed using LTQ-Orbitrap Velos Mass Spectrometer (MS). As trypsin 
hydrolyses the protein amide backbone selectively the peptide fragments act 




sequence databases. Further peptides may be fragmented in the MS to yield 
sequence information to confirm or refute the identity of the isolated proteins. 
The combination of MS data leads to high confidence identification of 
proteins of interest. Such MS data can then be used to apply bioinformatics 
tools to confidently identify the proteins present in the sample. Iwill further 
confirm the protein partners by using the endogenous TCHP 
immunoprecipitation, followed by specific immunoblot. Using protein pull-
down assays with tagged TCHP deletion mutants I will aim to discover 
regions of TCHP that are necessary to bind partner proteins. To study 
whether the identified TCHP-binding proteins have an impact on TCHP 
activity, the localization using confocal microscopy of TCHP-binding proteins 
will be explored in TCHP KD cells.  
 
	
6.4.2 Role of TCHP in post-ischaemic angiogenesis 
The role of the TCHP in post-ischaemic neovascularisation and blood flow 
recovery will be addressed using a murine model of critical limb ischaemia. 
For this proposal, Iwill generate mice with endothelial selective TCHP KO 
(Tchp-EC-KO) through breeding the conditional KO mice with mice carrying 
Cre recombinase under the Ve-cadherin promoter. Controls will consist of 
VE-cadherin Cre strain mice and mice homozygous for the loxP flanked 
allele.  
The basal cardiovascular phenotype of the Tchp-EC-KO mice will be 
characterized in the reference of 2 control strains.  An Ultrasonics Vevo 770 
high resolution ultrasound scanner unit will be used to assess standard LV 
(left ventricle) images to assess systolic and diastolic function (Meloni, 
Marchetti et al. 2013). 
Once the basal cardiovascular phenotype of KO mice has been 
characterized, limb ischaemia protocol will be initiated. Pre-clinical imaging of 
perfusion and neovascularization (angiogenesis and arteriogenesis). 




recovery in the mouse paws (at 3, 7, 14, and 21 days post-ischaemia) using 
the Moor FLPI-2 Doppler blood flow imager (Caporali, Meloni et al. 2011, 
Caporali, Meloni et al. 2015).  
 
6.5 Conclusion 
I have identified TCHP as a novel regulator of autophagy and EC function. 
Loss of TCHP function in ECs in vitro led to defective autophagy, resulting in 
accumulation of unfolded protein aggregates and SQSTM1; thus, impairing 
EC function. Moreover, the block of autophagic flux in ECs resulted in 
premature cellular senescence, appearance of SASP, including IL-6 and IL-8 
cytokine, and increased expression of p16. This phenotype is caused by 
activation of the mTOR pathway and was rescued by re-activation of 
autophagy by the mTOR inhibitor Torin-1. Ialso observed loss of TCHP and 
an increase of protein aggregates and SQSTM1 in the local vessel wall 
derived-ECs, from patients with vascular dysfunction and premature coronary 
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